{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:53:14Z","timestamp":1790977994465,"version":"4.1.0"},"reference-count":324,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170275"],"award-info":[{"award-number":["82170275"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bile acids (BAs), cholesterol-derived amphipathic metabolites which are traditionally regarded as digestive surfactants, are now recognized as pleiotropic signaling molecules that act through ligand-, receptor-, and tissue-specific mechanisms to maintain systemic homeostasis. They exert biological functions via nuclear receptors (FXR, PXR, VDR, CAR) and membrane receptors (TGR5, S1PR2, MRGPRX4). These receptors activate transcriptional and membrane-initiated programs, including FXR\u2013SHP\/FGF19 feedback, TGR5\u2013cAMP\u2013PKA signaling, S1PR2\u2013ERK\/AKT\/RhoA pathways, MRGPRX4-dependent Ca\n                    <jats:sup>2<\/jats:sup>\n                    \u207a signaling, PXR\/CAR\/VDR-driven detoxification responses, and non-receptor-mediated membrane and mitochondrial stress pathways. This review discusses how the diversity of BA structures, hepatic synthesis, conjugation, transportation, enterohepatic circulation, and microbiota-mediated transformation generates receptor- and tissue-specific signals. Furthermore, we summarize the physiological functions of BA signaling in lipid, glucose, and energy metabolism, intestinal epithelial integrity, mucosal immunity, neuroendocrine regulation, musculoskeletal adaptation, and renal water-salt balance. Additionally, we discuss the effects of disrupted BA signaling on cholestatic and metabolic liver diseases, alcohol-associated liver disease, hepatocellular carcinoma, inflammatory bowel disease, BA diarrhea, colorectal cancer, obesity, type 2 diabetes, atherosclerosis, and biliary tract diseases. Finally, the therapeutic strategies that modulate BA signaling, including the use of FXR and TGR5 agonists, FGF19 analogues, transporter inhibitors, enzyme-targeting methods, microbiota-based treatments, and hydrophilic BA therapies, are evaluated. By categorizing BA biology according to the production of ligands, receptor activation, tissue responses, and disease mechanisms, this review highlights BA signaling as an integrated regulatory network and a tractable therapeutic axis in health and disease.\n                  <\/jats:p>","DOI":"10.1186\/s43556-026-00603-4","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:47:48Z","timestamp":1790930868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bile acid signaling in health and disease"],"prefix":"10.1186","volume":"7","author":[{"given":"Zhezhe","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"1","key":"603_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","volume":"9","author":"JS Fleishman","year":"2024","unstructured":"Fleishman JS, Kumar S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024;9(1):97. https:\/\/doi.org\/10.1038\/s41392-024-01811-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"603_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","volume":"82","author":"CD Fuchs","year":"2025","unstructured":"Fuchs CD, Simbrunner B, Baumgartner M, Campbell C, Reiberger T, Trauner M. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025;82(1):134\u201353. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.032.","journal-title":"J Hepatol"},{"issue":"9","key":"603_CR3","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.3390\/ijms26094240","volume":"26","author":"X Lin","year":"2025","unstructured":"Lin X, Xia L, Zhou Y, Xie J, Tuo Q, Lin L, et al. Crosstalk between bile acids and intestinal epithelium: multidimensional roles of farnesoid X receptor and Takeda G protein receptor 5. Int J Mol Sci. 2025;26(9):4240. https:\/\/doi.org\/10.3390\/ijms26094240.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"603_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cmet.2025.11.010","volume":"38","author":"AP Chan","year":"2026","unstructured":"Chan AP, Jarrett KE, Lai RW, Brearley-Sholto MC, Cheng AS, Taveras MO, et al. Bile acids regulate lipid metabolism through selective actions on fatty acid absorption. Cell Metab. 2026;38(2):263-280.e10. https:\/\/doi.org\/10.1016\/j.cmet.2025.11.010.","journal-title":"Cell Metab"},{"issue":"5","key":"603_CR5","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s44161-025-00637-x","volume":"4","author":"Z Qi","year":"2025","unstructured":"Qi Z, Zhang W, Zhang P, Qu Y, Zhong H, Zhou L, et al. The gut microbiota-bile acid-TGR5 axis orchestrates platelet activation and atherothrombosis. Nat Cardiovasc Res. 2025;4(5):584\u2013601. https:\/\/doi.org\/10.1038\/s44161-025-00637-x.","journal-title":"Nat Cardiovasc Res"},{"issue":"8049","key":"603_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41586-024-08379-9","volume":"638","author":"TH Won","year":"2025","unstructured":"Won TH, Arifuzzaman M, Parkhurst CN, Miranda IC, Zhang B, Hu E, et al. Host metabolism balances microbial regulation of bile acid signalling. Nature. 2025;638(8049):216\u201324. https:\/\/doi.org\/10.1038\/s41586-024-08379-9.","journal-title":"Nature"},{"issue":"25","key":"603_CR7","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1016\/j.cell.2024.10.001","volume":"187","author":"J Yang","year":"2024","unstructured":"Yang J, Zhao T, Fan J, Zou H, Lan G, Guo F, et al. Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch. Cell. 2024;187(25):7164-7182.e18. https:\/\/doi.org\/10.1016\/j.cell.2024.10.001.","journal-title":"Cell"},{"issue":"7","key":"603_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","volume":"19","author":"CD Fuchs","year":"2022","unstructured":"Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol. 2022;19(7):432\u201350. https:\/\/doi.org\/10.1038\/s41575-021-00566-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"603_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/cs20230934","volume":"138","author":"CCJ Groenen","year":"2024","unstructured":"Groenen CCJ, Nguyen TA, Paulusma CC, van de Graaf SFJ. Bile salt signaling and bile salt-based therapies in cardiometabolic disease. Clin Sci (Lond). 2024;138(1):1\u201321. https:\/\/doi.org\/10.1042\/cs20230934.","journal-title":"Clin Sci (Lond)"},{"issue":"11","key":"603_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-024-01057-x","volume":"24","author":"MH Lee","year":"2024","unstructured":"Lee MH, Nuccio SP, Mohanty I, Hagey LR, Dorrestein PC, Chu H, et al. How bile acids and the microbiota interact to shape host immunity. Nat Rev Immunol. 2024;24(11):798\u2013809. https:\/\/doi.org\/10.1038\/s41577-024-01057-x.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"603_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1194\/jlr.c120000621","volume":"61","author":"GL Guo","year":"2020","unstructured":"Guo GL, Chiang JYL. Is CYP2C70 the key to new mouse models to understand bile acids in humans? J Lipid Res. 2020;61(3):269\u201371. https:\/\/doi.org\/10.1194\/jlr.c120000621.","journal-title":"J Lipid Res"},{"issue":"1","key":"603_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06321-3","volume":"7","author":"D Zheng","year":"2024","unstructured":"Zheng D, Ge K, Qu C, Sun T, Wang J, Jia W, et al. Comparative profiling of serum, urine, and feces bile acids in humans, rats, and mice. Commun Biol. 2024;7(1):641. https:\/\/doi.org\/10.1038\/s42003-024-06321-3.","journal-title":"Commun Biol"},{"issue":"1","key":"603_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40168-021-01101-1","volume":"9","author":"DV Guzior","year":"2021","unstructured":"Guzior DV, Quinn RA. Review: microbial transformations of human bile acids. Microbiome. 2021;9(1):140. https:\/\/doi.org\/10.1186\/s40168-021-01101-1.","journal-title":"Microbiome"},{"issue":"7797","key":"603_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","volume":"579","author":"RA Quinn","year":"2020","unstructured":"Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020;579(7797):123\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2047-9.","journal-title":"Nature"},{"issue":"8000","key":"603_CR15","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/s41586-023-06990-w","volume":"626","author":"B Rimal","year":"2024","unstructured":"Rimal B, Collins SL, Tanes CE, Rocha ER, Granda MA, Solanki S, et al. Bile salt hydrolase catalyses formation of amine-conjugated bile acids. Nature. 2024;626(8000):859\u201363. https:\/\/doi.org\/10.1038\/s41586-023-06990-w.","journal-title":"Nature"},{"issue":"1","key":"603_CR16","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1038\/s41467-026-68556-4","volume":"17","author":"LN Lucas","year":"2026","unstructured":"Lucas LN, Jillella M, Cattaneo LE, Gangwar B, Zhang Q, Clay AP, et al. Investigation of bile salt hydrolase activity in human gut bacteria reveals production of conjugated secondary bile acids. Nat Commun. 2026;17(1):3077. https:\/\/doi.org\/10.1038\/s41467-026-68556-4.","journal-title":"Nat Commun"},{"key":"603_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107845","volume":"218","author":"M Fan","year":"2025","unstructured":"Fan M, Yang Z, Jin L, Huang W. Differential roles of individual bile acid in physiology and disease. Pharmacol Res. 2025;218:107845. https:\/\/doi.org\/10.1016\/j.phrs.2025.107845.","journal-title":"Pharmacol Res"},{"issue":"11","key":"603_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116046","volume":"23","author":"T Katafuchi","year":"2022","unstructured":"Katafuchi T, Makishima M. Molecular basis of bile acid-FXR-FGF15\/19 signaling axis. Int J Mol Sci. 2022;23(11):6046. https:\/\/doi.org\/10.3390\/ijms23116046.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"603_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.32405","volume":"76","author":"MJ Mayo","year":"2022","unstructured":"Mayo MJ. Mechanisms and molecules: what are the treatment targets for primary biliary cholangitis? Hepatology. 2022;76(2):518\u201331. https:\/\/doi.org\/10.1002\/hep.32405.","journal-title":"Hepatology"},{"issue":"6","key":"603_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.dld.2010.03.015","volume":"42","author":"L Maillette de Buy Wenniger","year":"2010","unstructured":"Maillette de Buy Wenniger L, Beuers U. Bile salts and cholestasis. Dig Liver Dis. 2010;42(6):409\u201318. https:\/\/doi.org\/10.1016\/j.dld.2010.03.015.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"603_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","volume":"3","author":"JYL Chiang","year":"2013","unstructured":"Chiang JYL. Bile acid metabolism and signaling. Compr Physiol. 2013;3(3):1191\u2013212. https:\/\/doi.org\/10.1002\/cphy.c120023.","journal-title":"Compr Physiol"},{"issue":"10","key":"603_CR22","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1021\/acs.jpcb.3c00274","volume":"127","author":"NA Jamuna","year":"2023","unstructured":"Jamuna NA, Kamalakshan A, Dandekar BR, Chittilappilly Devassy AM, Mondal J, Mandal S. Mechanistic insight into the amyloid fibrillation inhibition of hen egg white lysozyme by three different bile acids. J Phys Chem B. 2023;127(10):2198\u2013213. https:\/\/doi.org\/10.1021\/acs.jpcb.3c00274.","journal-title":"J Phys Chem B"},{"issue":"5","key":"603_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41575-024-00896-2","volume":"21","author":"JM Ridlon","year":"2024","unstructured":"Ridlon JM, Gaskins HR. Another renaissance for bile acid gastrointestinal microbiology. Nat Rev Gastroenterol Hepatol. 2024;21(5):348\u201364. https:\/\/doi.org\/10.1038\/s41575-024-00896-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"603_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1890710","volume":"17","author":"F Yang","year":"2026","unstructured":"Yang F, Wei T, Liu K, Chu H, Yang L. Bile acid signaling: from dynamic pool composition to inter-organ communication. Front Endocrinol (Lausanne). 2026;17:1890710. https:\/\/doi.org\/10.3389\/fendo.2026.1890710.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5418","key":"603_CR25","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284(5418):1365\u20138. https:\/\/doi.org\/10.1126\/science.284.5418.1365.","journal-title":"Science"},{"issue":"5418","key":"603_CR26","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362\u20135. https:\/\/doi.org\/10.1126\/science.284.5418.1362.","journal-title":"Science"},{"issue":"5","key":"603_CR27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/s0006-291x(02)02550-0","volume":"298","author":"T Maruyama","year":"2002","unstructured":"Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298(5):714\u20139. https:\/\/doi.org\/10.1016\/s0006-291x(02)02550-0.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"603_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/s1097-2765(00)80348-2","volume":"3","author":"H Wang","year":"1999","unstructured":"Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR. Mol Cell. 1999;3(5):543\u201353. https:\/\/doi.org\/10.1016\/s1097-2765(00)80348-2.","journal-title":"Mol Cell"},{"issue":"4","key":"603_CR29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s1097-2765(03)00112-6","volume":"11","author":"LZ Mi","year":"2003","unstructured":"Mi LZ, Devarakonda S, Harp JM, Han Q, Pellicciari R, Willson TM, et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell. 2003;11(4):1093\u2013100. https:\/\/doi.org\/10.1016\/s1097-2765(03)00112-6.","journal-title":"Mol Cell"},{"issue":"2","key":"603_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","volume":"17","author":"SI Sayin","year":"2013","unstructured":"Sayin SI, Wahlstr\u00f6m A, Felin J, J\u00e4ntti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225\u201335. https:\/\/doi.org\/10.1016\/j.cmet.2013.01.003.","journal-title":"Cell Metab"},{"issue":"1","key":"603_CR31","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1038\/ncomms3384","volume":"4","author":"F Li","year":"2013","unstructured":"Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013;4(1):2384. https:\/\/doi.org\/10.1038\/ncomms3384.","journal-title":"Nat Commun"},{"issue":"1","key":"603_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13578-023-01053-z","volume":"13","author":"C Xing","year":"2023","unstructured":"Xing C, Huang X, Wang D, Yu D, Hou S, Cui H, et al. Roles of bile acids signaling in neuromodulation under physiological and pathological conditions. Cell Biosci. 2023;13(1):106. https:\/\/doi.org\/10.1186\/s13578-023-01053-z.","journal-title":"Cell Biosci"},{"issue":"7885","key":"603_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41586-021-03832-5","volume":"599","author":"Y Sato","year":"2021","unstructured":"Sato Y, Atarashi K, Plichta DR, Arai Y, Sasajima S, Kearney SM, et al. Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians. Nature. 2021;599(7885):458\u201364. https:\/\/doi.org\/10.1038\/s41586-021-03832-5.","journal-title":"Nature"},{"key":"603_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114987","volume":"164","author":"N Yang","year":"2023","unstructured":"Yang N, Sun R, Zhang X, Wang J, Wang L, Zhu H, et al. Alternative pathway of bile acid biosynthesis contributes to ameliorate NASH after induction of NAMPT\/NAD(+)\/SIRT1 axis. Biomed Pharmacother. 2023;164:114987. https:\/\/doi.org\/10.1016\/j.biopha.2023.114987.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"603_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00018-022-04278-2","volume":"79","author":"T Re\u017een","year":"2022","unstructured":"Re\u017een T, Rozman D, Kov\u00e1cs T, Kov\u00e1cs P, Sipos A, Bai P, et al. The role of bile acids in carcinogenesis. Cell Mol Life Sci. 2022;79(5):243. https:\/\/doi.org\/10.1007\/s00018-022-04278-2.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"603_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/s1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6(3):517\u201326. https:\/\/doi.org\/10.1016\/s1097-2765(00)00051-4.","journal-title":"Mol Cell"},{"issue":"4","key":"603_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","volume":"2","author":"T Inagaki","year":"2005","unstructured":"Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217\u201325. https:\/\/doi.org\/10.1016\/j.cmet.2005.09.001.","journal-title":"Cell Metab"},{"issue":"37","key":"603_CR38","doi-asserted-by":"publisher","first-page":"27277","DOI":"10.1074\/jbc.m704244200","volume":"282","author":"BC Lin","year":"2007","unstructured":"Lin BC, Wang M, Blackmore C, Desnoyers LR. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem. 2007;282(37):27277\u201384. https:\/\/doi.org\/10.1074\/jbc.m704244200.","journal-title":"J Biol Chem"},{"issue":"11","key":"603_CR39","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1124\/dmd.124.001694","volume":"52","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang Y, Hu Y, Wu Q, Gui L, Zeng W, et al. CYP8B1 catalyzes 12alpha-hydroxylation of C27 bile acid: in vitro conversion of dihydroxycoprostanic acid into trihydroxycoprostanic acid. Drug Metab Dispos. 2024;52(11):1234\u201343. https:\/\/doi.org\/10.1124\/dmd.124.001694.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"603_CR40","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.r900010-jlr200","volume":"50","author":"JYL Chiang","year":"2009","unstructured":"Chiang JYL. Bile acids: regulation of synthesis. J Lipid Res. 2009;50(10):1955\u201366. https:\/\/doi.org\/10.1194\/jlr.r900010-jlr200.","journal-title":"J Lipid Res"},{"key":"603_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116313","volume":"225","author":"XJ Li","year":"2024","unstructured":"Li XJ, Fang C, Zhao RH, Zou L, Miao H, Zhao YY. Bile acid metabolism in health and ageing-related diseases. Biochem Pharmacol. 2024;225:116313. https:\/\/doi.org\/10.1016\/j.bcp.2024.116313.","journal-title":"Biochem Pharmacol"},{"issue":"32","key":"603_CR42","doi-asserted-by":"publisher","first-page":"24529","DOI":"10.1074\/jbc.m110.127779","volume":"285","author":"JE Drury","year":"2010","unstructured":"Drury JE, Mindnich R, Penning TM. Characterization of disease-related 5beta-reductase (AKR1D1) mutations reveals their potential to cause bile acid deficiency. J Biol Chem. 2010;285(32):24529\u201337. https:\/\/doi.org\/10.1074\/jbc.m110.127779.","journal-title":"J Biol Chem"},{"issue":"12","key":"603_CR43","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.bbamcr.2006.09.001","volume":"1763","author":"S Ferdinandusse","year":"2006","unstructured":"Ferdinandusse S, Houten SM. Peroxisomes and bile acid biosynthesis. Biochim Biophys Acta Mol Cell Res. 2006;1763(12):1427\u201340. https:\/\/doi.org\/10.1016\/j.bbamcr.2006.09.001.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"12","key":"603_CR44","doi-asserted-by":"publisher","first-page":"11336","DOI":"10.1074\/jbc.m310258200","volume":"279","author":"C Stedman","year":"2004","unstructured":"Stedman C, Robertson G, Coulter S, Liddle C. Feed-forward regulation of bile acid detoxification by CYP3A4. J Biol Chem. 2004;279(12):11336\u201343. https:\/\/doi.org\/10.1074\/jbc.m310258200.","journal-title":"J Biol Chem"},{"issue":"2","key":"603_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.livres.2019.05.001","volume":"3","author":"WM Pandak","year":"2019","unstructured":"Pandak WM, Kakiyama G. The acidic pathway of bile acid synthesis: not just an alternative pathway. Liver Res. 2019;3(2):88\u201398. https:\/\/doi.org\/10.1016\/j.livres.2019.05.001.","journal-title":"Liver Res"},{"issue":"3","key":"603_CR46","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1074\/jbc.M111.305789","volume":"287","author":"T Li","year":"2012","unstructured":"Li T, Francl JM, Boehme S, Ochoa A, Zhang Y, Klaassen CD, et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol Chem. 2012;287(3):1861\u201373. https:\/\/doi.org\/10.1074\/jbc.M111.305789.","journal-title":"J Biol Chem"},{"issue":"9","key":"603_CR47","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1194\/jlr.m800140-jlr200","volume":"49","author":"T Li","year":"2008","unstructured":"Li T, Ma H, Chiang JYL. TGFbeta1, TNFalpha, and insulin signaling crosstalk in regulation of the rat cholesterol 7alpha-hydroxylase gene expression. J Lipid Res. 2008;49(9):1981\u20139. https:\/\/doi.org\/10.1194\/jlr.m800140-jlr200.","journal-title":"J Lipid Res"},{"key":"603_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2023.109517","volume":"124","author":"A Gregor","year":"2024","unstructured":"Gregor A, Panteva V, Bruckberger S, Au\u00f1on-Lopez A, Blahova S, Blahova V, et al. Energy and macronutrient restriction regulate bile acid homeostasis. J Nutr Biochem. 2024;124:109517. https:\/\/doi.org\/10.1016\/j.jnutbio.2023.109517.","journal-title":"J Nutr Biochem"},{"issue":"1","key":"603_CR49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cmet.2024.09.008","volume":"37","author":"L Song","year":"2025","unstructured":"Song L, Hou Y, Xu D, Dai X, Luo J, Liu Y, et al. Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress. Cell Metab. 2025;37(1):104-20.e9. https:\/\/doi.org\/10.1016\/j.cmet.2024.09.008.","journal-title":"Cell Metab"},{"issue":"1","key":"603_CR50","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/hep.27240","volume":"61","author":"FM Vaz","year":"2015","unstructured":"Vaz FM, Paulusma CC, Huidekoper H, de Ru M, Lim C, Koster J, et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology. 2015;61(1):260\u20137. https:\/\/doi.org\/10.1002\/hep.27240.","journal-title":"Hepatology"},{"issue":"5","key":"603_CR51","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/hep.29251","volume":"66","author":"D Slijepcevic","year":"2017","unstructured":"Slijepcevic D, Roscam Abbing RLP, Katafuchi T, Blank A, Donkers JM, van Hoppe S, et al. Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice. Hepatology. 2017;66(5):1631\u201343. https:\/\/doi.org\/10.1002\/hep.29251.","journal-title":"Hepatology"},{"issue":"9","key":"603_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.100979","volume":"14","author":"X Tan","year":"2024","unstructured":"Tan X, Xiang Y, Shi J, Chen L, Yu D. Targeting NTCP for liver disease treatment: a promising strategy. J Pharm Anal. 2024;14(9):100979. https:\/\/doi.org\/10.1016\/j.jpha.2024.100979.","journal-title":"J Pharm Anal"},{"issue":"1","key":"603_CR53","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s42003-025-07908-0","volume":"8","author":"C Gruget","year":"2025","unstructured":"Gruget C, Reddy BG, Moore JM. A structural and mechanistic model for BSEP dysfunction in PFIC2 cholestatic disease. Commun Biol. 2025;8(1):531. https:\/\/doi.org\/10.1038\/s42003-025-07908-0.","journal-title":"Commun Biol"},{"issue":"6","key":"603_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101641","volume":"45","author":"T Ren","year":"2021","unstructured":"Ren T, Pang L, Dai W, Wu S, Kong J. Regulatory mechanisms of the bile salt export pump (BSEP\/ABCB11) and its role in related diseases. Clin Res Hepatol Gastroenterol. 2021;45(6):101641. https:\/\/doi.org\/10.1016\/j.clinre.2021.101641.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"603_CR55","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1038\/s41467-023-43109-1","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Irobalieva RN, Kowal J, Ni D, Nosol K, Bang-S\u00f8rensen R, et al. Structural basis of bile salt extrusion and small-molecule inhibition in human BSEP. Nat Commun. 2023;14(1):7296. https:\/\/doi.org\/10.1038\/s41467-023-43109-1.","journal-title":"Nat Commun"},{"issue":"4","key":"603_CR56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1124\/dmd.113.055772","volume":"42","author":"D Keppler","year":"2014","unstructured":"Keppler D. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos. 2014;42(4):561\u20135. https:\/\/doi.org\/10.1124\/dmd.113.055772.","journal-title":"Drug Metab Dispos"},{"key":"603_CR57","doi-asserted-by":"publisher","first-page":"1085621","DOI":"10.3389\/fphar.2022.1085621","volume":"13","author":"JJ Beaudoin","year":"2023","unstructured":"Beaudoin JJ, Yang K, Adiwidjaja J, Taneja G, Watkins PB, Siler SQ, et al. Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition. Front Pharmacol. 2023;13:1085621. https:\/\/doi.org\/10.3389\/fphar.2022.1085621.","journal-title":"Front Pharmacol"},{"issue":"1","key":"603_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-025-00451-x","volume":"15","author":"TA Mohammed","year":"2025","unstructured":"Mohammed TA, Zalzala MH. The role of hepatobiliary transporters in bile acid homeostasis. Egypt Liver J. 2025;15(1):43. https:\/\/doi.org\/10.1186\/s43066-025-00451-x.","journal-title":"Egypt Liver J"},{"key":"603_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110835","volume":"132","author":"N Yang","year":"2020","unstructured":"Yang N, Dong YQ, Jia GX, Fan SM, Li SZ, Yang SS, et al. ASBT(SLC10A2): a promising target for treatment of diseases and drug discovery. Biomed Pharmacother. 2020;132:110835. https:\/\/doi.org\/10.1016\/j.biopha.2020.110835.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"603_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2024.101392","volume":"18","author":"K Sudo","year":"2024","unstructured":"Sudo K, Delmas-Eliason A, Soucy S, Barrack KE, Liu J, Balasubramanian A, et al. Quantifying forms and functions of enterohepatic bile acid pools in mice. Cell Mol Gastroenterol Hepatol. 2024;18(6):101392. https:\/\/doi.org\/10.1016\/j.jcmgh.2024.101392.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"603_CR61","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1074\/jbc.m412752200","volume":"280","author":"PA Dawson","year":"2005","unstructured":"Dawson PA, Hubbert M, Haywood J, Craddock AL, Zerangue N, Christian WV, et al. The heteromeric organic solute transporter \u03b1-\u03b2, Ost\u03b1-Ost\u03b2, is an ileal basolateral bile acid transporter. J Biol Chem. 2005;280(8):6960\u20138. https:\/\/doi.org\/10.1074\/jbc.m412752200.","journal-title":"J Biol Chem"},{"issue":"6","key":"603_CR62","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1194\/jlr.r054114","volume":"56","author":"PA Dawson","year":"2015","unstructured":"Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res. 2015;56(6):1085\u201399. https:\/\/doi.org\/10.1194\/jlr.r054114.","journal-title":"J Lipid Res"},{"issue":"1","key":"603_CR63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.chembiol.2024.05.009","volume":"32","author":"L Han","year":"2025","unstructured":"Han L, Pendleton A, Singh A, Xu R, Scott SA, Palma JA, et al. Chemoproteomic profiling of substrate specificity in gut microbiota-associated bile salt hydrolases. Cell Chem Biol. 2025;32(1):145-56.e9. https:\/\/doi.org\/10.1016\/j.chembiol.2024.05.009.","journal-title":"Cell Chem Biol"},{"key":"603_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/femsre\/fuaf016","volume":"49","author":"SL Daniel","year":"2025","unstructured":"Daniel SL, Ridlon JM. Clostridium scindens: history and current outlook for a keystone species in the mammalian gut involved in bile acid and steroid metabolism. FEMS Microbiol Rev. 2025;49:fuaf016. https:\/\/doi.org\/10.1093\/femsre\/fuaf016.","journal-title":"FEMS Microbiol Rev"},{"issue":"1","key":"603_CR65","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1194\/jlr.m020313","volume":"53","author":"JM Ridlon","year":"2012","unstructured":"Ridlon JM, Hylemon PB. Identification and characterization of two bile acid coenzyme A transferases from Clostridium scindens, a bile acid 7\u03b1-dehydroxylating intestinal bacterium. J Lipid Res. 2012;53(1):66\u201376. https:\/\/doi.org\/10.1194\/jlr.m020313.","journal-title":"J Lipid Res"},{"key":"603_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2022.105533","volume":"87","author":"V Kastrinou Lampou","year":"2023","unstructured":"Kastrinou Lampou V, Poller B, Huth F, Fischer A, Kullak-Ublick GA, Arand M, et al. Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes. Toxicol In Vitro. 2023;87:105533. https:\/\/doi.org\/10.1016\/j.tiv.2022.105533.","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"603_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100214","volume":"3","author":"V Bidault-Jourdainne","year":"2021","unstructured":"Bidault-Jourdainne V, Merlen G, Gl\u00e9nisson M, Doignon I, Garcin I, P\u00e9an N, et al. TGR5 controls bile acid composition and gallbladder function to protect the liver from bile acid overload. JHEP Rep. 2021;3(2):100214. https:\/\/doi.org\/10.1016\/j.jhepr.2020.100214.","journal-title":"JHEP Rep"},{"issue":"14","key":"603_CR68","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3748\/wjg.15.1677","volume":"15","author":"MJ Perez","year":"2009","unstructured":"Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15(14):1677\u201389. https:\/\/doi.org\/10.3748\/wjg.15.1677.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"603_CR69","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","volume":"35","author":"J Kuang","year":"2023","unstructured":"Kuang J, Wang J, Li Y, Li M, Zhao M, Ge K, et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. Cell Metab. 2023;35(10):1752-1766.e8. https:\/\/doi.org\/10.1016\/j.cmet.2023.07.011.","journal-title":"Cell Metab"},{"key":"603_CR70","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.freeradbiomed.2025.06.039","volume":"238","author":"W Wang","year":"2025","unstructured":"Wang W, Li L, Li X, Chen J, Wang R, Yang Q, et al. FXR overexpression alleviates cholestasis via NLRC4 inflammasome suppression and bile acid homeostasis regulation. Free Radic Biol Med. 2025;238:152\u201368. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2025.06.039.","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"603_CR71","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/ph18091424","volume":"18","author":"S Fiorucci","year":"2025","unstructured":"Fiorucci S, Urbani G, Distrutti E, Biagioli M. Obeticholic acid and other Farnesoid-X-Receptor (FXR) agonists in the treatment of liver disorders. Pharmaceuticals (Basel). 2025;18(9):1424. https:\/\/doi.org\/10.3390\/ph18091424.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"603_CR72","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/s1097-2765(00)00050-2","volume":"6","author":"TT Lu","year":"2000","unstructured":"Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6(3):507\u201315. https:\/\/doi.org\/10.1016\/s1097-2765(00)00050-2.","journal-title":"Mol Cell"},{"issue":"49","key":"603_CR73","doi-asserted-by":"publisher","first-page":"41334","DOI":"10.1074\/jbc.m112.421834","volume":"287","author":"S Kir","year":"2012","unstructured":"Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ. Nuclear receptors HNF4\u03b1 and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem. 2012;287(49):41334\u201341. https:\/\/doi.org\/10.1074\/jbc.m112.421834.","journal-title":"J Biol Chem"},{"issue":"3","key":"603_CR74","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/hep.25740","volume":"56","author":"B Kong","year":"2012","unstructured":"Kong B, Wang L, Chiang JYL, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology. 2012;56(3):1034\u201343. https:\/\/doi.org\/10.1002\/hep.25740.","journal-title":"Hepatology"},{"issue":"1","key":"603_CR75","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1038\/s41467-020-17363-6","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, Gunewardena S, Li F, Matye DJ, Chen C, Chao X, et al. An FGF15\/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis. Nat Commun. 2020;11(1):3612. https:\/\/doi.org\/10.1038\/s41467-020-17363-6.","journal-title":"Nat Commun"},{"issue":"6024","key":"603_CR76","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331(6024):1621\u20134. https:\/\/doi.org\/10.1126\/science.1198363.","journal-title":"Science"},{"issue":"2","key":"603_CR77","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1194\/jlr.m027094","volume":"54","author":"X Wu","year":"2013","unstructured":"Wu X, Ge H, Baribault H, Gupte J, Weiszmann J, Lemon B, et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res. 2013;54(2):325\u201332. https:\/\/doi.org\/10.1194\/jlr.m027094.","journal-title":"J Lipid Res"},{"issue":"31","key":"603_CR78","doi-asserted-by":"publisher","first-page":"28857","DOI":"10.1074\/jbc.m011610200","volume":"276","author":"M Ananthanarayanan","year":"2001","unstructured":"Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ. Human bile salt export pump promoter is transactivated by the farnesoid X receptor\/bile acid receptor. J Biol Chem. 2001;276(31):28857\u201365. https:\/\/doi.org\/10.1074\/jbc.m011610200.","journal-title":"J Biol Chem"},{"issue":"42","key":"603_CR79","doi-asserted-by":"publisher","first-page":"29749","DOI":"10.1074\/jbc.274.42.29749","volume":"274","author":"J Grober","year":"1999","unstructured":"Grober J, Zaghini I, Fujii H, Jones SA, Kliewer SA, Willson TM, et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor\/9-cis-retinoic acid receptor heterodimer. J Biol Chem. 1999;274(42):29749\u201354. https:\/\/doi.org\/10.1074\/jbc.274.42.29749.","journal-title":"J Biol Chem"},{"issue":"3","key":"603_CR80","doi-asserted-by":"publisher","first-page":"G476","DOI":"10.1152\/ajpgi.00430.2005","volume":"290","author":"JF Landrier","year":"2006","unstructured":"Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am J Physiol Gastrointest Liver Physiol. 2006;290(3):G476\u201385. https:\/\/doi.org\/10.1152\/ajpgi.00430.2005.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"603_CR81","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1053\/gast.2001.25503","volume":"121","author":"LA Denson","year":"2001","unstructured":"Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology. 2001;121(1):140\u20137. https:\/\/doi.org\/10.1053\/gast.2001.25503.","journal-title":"Gastroenterology"},{"issue":"6","key":"603_CR82","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1073\/pnas.051551698","volume":"98","author":"JL Staudinger","year":"2001","unstructured":"Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001;98(6):3369\u201374. https:\/\/doi.org\/10.1073\/pnas.051551698.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"603_CR83","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jhep.2003.12.001","volume":"40","author":"GU Denk","year":"2004","unstructured":"Denk GU, Soroka CJ, Takeyama Y, Chen WS, Schuetz JD, Boyer JL. Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. J Hepatol. 2004;40(4):585\u201391. https:\/\/doi.org\/10.1016\/j.jhep.2003.12.001.","journal-title":"J Hepatol"},{"key":"603_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100325","volume":"24","author":"SI P\u00e9rez-Pineda","year":"2021","unstructured":"P\u00e9rez-Pineda SI, Bayl\u00f3n-Pacheco L, Esp\u00edritu-Gordillo P, Tsutsumi V, Rosales-Encina JL. Effect of bile acids on the expression of MRP3 and MRP4: an in vitro study in HepG2 cell line. Ann Hepatol. 2021;24:100325. https:\/\/doi.org\/10.1016\/j.aohep.2021.100325.","journal-title":"Ann Hepatol"},{"issue":"21","key":"603_CR85","doi-asserted-by":"publisher","first-page":"22250","DOI":"10.1074\/jbc.m314111200","volume":"279","author":"M Assem","year":"2004","unstructured":"Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem. 2004;279(21):22250\u20137. https:\/\/doi.org\/10.1074\/jbc.m314111200.","journal-title":"J Biol Chem"},{"issue":"1","key":"603_CR86","doi-asserted-by":"publisher","first-page":"G126","DOI":"10.1152\/ajpgi.00522.2010","volume":"299","author":"S Xu","year":"2010","unstructured":"Xu S, Weerachayaphorn J, Cai SY, Soroka CJ, Boyer JL. Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. Am J Physiol Gastrointest Liver Physiol. 2010;299(1):G126\u201335. https:\/\/doi.org\/10.1152\/ajpgi.00522.2010.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"603_CR87","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.bbrc.2006.10.027","volume":"351","author":"W Jiang","year":"2006","unstructured":"Jiang W, Miyamoto T, Kakizawa T, Nishio S, Oiwa A, Takeda T, et al. Inhibition of LXRalpha signaling by vitamin D receptor: possible role of VDR in bile acid synthesis. Biochem Biophys Res Commun. 2006;351(1):176\u201384. https:\/\/doi.org\/10.1016\/j.bbrc.2006.10.027.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"603_CR88","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1210\/me.2009-0482","volume":"24","author":"S Han","year":"2010","unstructured":"Han S, Li T, Ellis E, Strom S, Chiang JYL. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol. 2010;24(6):1151\u201364. https:\/\/doi.org\/10.1210\/me.2009-0482.","journal-title":"Mol Endocrinol"},{"issue":"4","key":"603_CR89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1208\/s12248-022-00719-9","volume":"24","author":"K Noh","year":"2022","unstructured":"Noh K, Chow ECY, Quach HP, Groothuis GMM, Tirona RG, Pang KS. Significance of the vitamin D receptor on crosstalk with nuclear receptors and regulation of enzymes and transporters. AAPS J. 2022;24(4):71. https:\/\/doi.org\/10.1208\/s12248-022-00719-9.","journal-title":"AAPS J"},{"issue":"4","key":"603_CR90","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3177\/jnsv.66.370","volume":"66","author":"S Nishida","year":"2020","unstructured":"Nishida S, Ishizawa M, Kato S, Makishima M. Vitamin D receptor deletion changes bile acid composition in mice orally administered chenodeoxycholic acid. J Nutr Sci Vitaminol. 2020;66(4):370\u20134. https:\/\/doi.org\/10.3177\/jnsv.66.370.","journal-title":"J Nutr Sci Vitaminol"},{"issue":"5571","key":"603_CR91","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1126\/science.1070477","volume":"296","author":"M Makishima","year":"2002","unstructured":"Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, et al. Vitamin D receptor as an intestinal bile acid sensor. Science. 2002;296(5571):1313\u20136. https:\/\/doi.org\/10.1126\/science.1070477.","journal-title":"Science"},{"issue":"10","key":"603_CR92","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1124\/dmd.108.021501","volume":"36","author":"T Matsubara","year":"2008","unstructured":"Matsubara T, Yoshinari K, Aoyama K, Sugawara M, Sekiya Y, Nagata K, et al. Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug Metab Dispos. 2008;36(10):2058\u201363. https:\/\/doi.org\/10.1124\/dmd.108.021501.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"603_CR93","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1194\/jlr.m044420","volume":"55","author":"J Cheng","year":"2014","unstructured":"Cheng J, Fang ZZ, Kim JH, Krausz KW, Tanaka N, Chiang JYL, et al. Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. J Lipid Res. 2014;55(3):455\u201365. https:\/\/doi.org\/10.1194\/jlr.m044420.","journal-title":"J Lipid Res"},{"issue":"3","key":"603_CR94","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1124\/mol.65.3.720","volume":"65","author":"I Echchgadda","year":"2004","unstructured":"Echchgadda I, Song CS, Roy AK, Chatterjee B. Dehydroepiandrosterone sulfotransferase is a target for transcriptional induction by the vitamin D receptor. Mol Pharmacol. 2004;65(3):720\u20139. https:\/\/doi.org\/10.1124\/mol.65.3.720.","journal-title":"Mol Pharmacol"},{"issue":"11","key":"603_CR95","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae134","volume":"165","author":"MB Meyer","year":"2024","unstructured":"Meyer MB, Lee SM, Towne JM, Cichanski SR, Kaufmann M, Jones G, et al. In vivo contribution of Cyp24a1 promoter vitamin D response elements. Endocrinology. 2024;165(11):bqae134. https:\/\/doi.org\/10.1210\/endocr\/bqae134.","journal-title":"Endocrinology"},{"issue":"6","key":"603_CR96","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1210\/en.2018-00110","volume":"159","author":"KH Kim","year":"2018","unstructured":"Kim KH, Choi JM, Li F, Arizpe A, Wooton-Kee CR, Anakk S, et al. Xenobiotic nuclear receptor signaling determines molecular pathogenesis of progressive familial intrahepatic cholestasis. Endocrinology. 2018;159(6):2435\u201346. https:\/\/doi.org\/10.1210\/en.2018-00110.","journal-title":"Endocrinology"},{"issue":"7","key":"603_CR97","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1073\/pnas.0630614100","volume":"100","author":"W Huang","year":"2003","unstructured":"Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, et al. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci U S A. 2003;100(7):4156\u201361. https:\/\/doi.org\/10.1073\/pnas.0630614100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"603_CR98","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1124\/mol.65.2.292","volume":"65","author":"SPS Saini","year":"2004","unstructured":"Saini SPS, Sonoda J, Xu L, Toma D, Uppal H, Mu Y, et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol. 2004;65(2):292\u2013300. https:\/\/doi.org\/10.1124\/mol.65.2.292.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"603_CR99","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/hep.20784","volume":"42","author":"M Wagner","year":"2005","unstructured":"Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology. 2005;42(2):420\u201330. https:\/\/doi.org\/10.1002\/hep.20784.","journal-title":"Hepatology"},{"issue":"6","key":"603_CR100","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s11605-011-1473-2","volume":"15","author":"J Chai","year":"2011","unstructured":"Chai J, Luo D, Wu X, Wang H, He Y, Li Q, et al. Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis. J Gastrointest Surg. 2011;15(6):996\u20131004. https:\/\/doi.org\/10.1007\/s11605-011-1473-2.","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"603_CR101","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1210\/me.2010-0460","volume":"25","author":"T Li","year":"2011","unstructured":"Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol. 2011;25(6):1066\u201371. https:\/\/doi.org\/10.1210\/me.2010-0460.","journal-title":"Mol Endocrinol"},{"issue":"3","key":"603_CR102","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","volume":"65","author":"M Reich","year":"2016","unstructured":"Reich M, Deutschmann K, Sommerfeld A, Klindt C, Kluge S, Kubitz R, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut. 2016;65(3):487\u2013501. https:\/\/doi.org\/10.1136\/gutjnl-2015-309458.","journal-title":"Gut"},{"issue":"3","key":"603_CR103","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/cpdd.34","volume":"2","author":"RJ Hodge","year":"2013","unstructured":"Hodge RJ, Lin J, Vasist Johnson LS, Gould EP, Bowers GD, Nunez DJ. Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Dev. 2013;2(3):213\u201322. https:\/\/doi.org\/10.1002\/cpdd.34.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"603_CR104","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/hep.24681","volume":"55","author":"E Studer","year":"2012","unstructured":"Studer E, Zhou X, Zhao R, Wang Y, Takabe K, Nagahashi M, et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology. 2012;55(1):267\u201376. https:\/\/doi.org\/10.1002\/hep.24681.","journal-title":"Hepatology"},{"issue":"2","key":"603_CR105","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00109-020-02032-4","volume":"99","author":"L Hou","year":"2021","unstructured":"Hou L, Zhang Z, Yang L, Chang N, Zhao X, Zhou X, et al. NLRP3 inflammasome priming and activation in cholestatic liver injury via the sphingosine 1-phosphate\/S1P receptor 2\/G\u03b1(12\/13)\/MAPK signaling pathway. J Mol Med. 2021;99(2):273\u201388. https:\/\/doi.org\/10.1007\/s00109-020-02032-4.","journal-title":"J Mol Med"},{"issue":"1","key":"603_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0317568","volume":"20","author":"A Miyagawa-Hayashino","year":"2025","unstructured":"Miyagawa-Hayashino A, Imura T, Takezawa T, Hirai M, Shibata S, Ogi H, et al. Activation of S1PR2 on macrophages and the hepatocyte S1PR2\/RhoA\/ROCK1\/MLC2 pathway in vanishing bile duct syndrome. PLoS ONE. 2025;20(1):e0317568. https:\/\/doi.org\/10.1371\/journal.pone.0317568.","journal-title":"PLoS ONE"},{"issue":"4","key":"603_CR107","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/hep.27592","volume":"61","author":"M Nagahashi","year":"2015","unstructured":"Nagahashi M, Takabe K, Liu R, Peng K, Wang X, Wang Y, et al. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology. 2015;61(4):1216\u201326. https:\/\/doi.org\/10.1002\/hep.27592.","journal-title":"Hepatology"},{"issue":"52","key":"603_CR108","doi-asserted-by":"publisher","first-page":"30988","DOI":"10.1074\/jbc.m115.668277","volume":"290","author":"R Liu","year":"2015","unstructured":"Liu R, Li X, Qiang X, Luo L, Hylemon PB, Jiang Z, et al. Taurocholate induces cyclooxygenase-2 expression via the sphingosine 1-phosphate receptor 2 in a human cholangiocarcinoma cell line. J Biol Chem. 2015;290(52):30988\u20131002. https:\/\/doi.org\/10.1074\/jbc.m115.668277.","journal-title":"J Biol Chem"},{"key":"603_CR109","doi-asserted-by":"publisher","DOI":"10.7554\/elife.48431","volume":"8","author":"H Yu","year":"2019","unstructured":"Yu H, Zhao T, Liu S, Wu Q, Johnson O, Wu Z, et al. MRGPRX4 is a bile acid receptor for human cholestatic itch. Elife. 2019;8:e48431. https:\/\/doi.org\/10.7554\/elife.48431.","journal-title":"Elife"},{"issue":"21","key":"603_CR110","doi-asserted-by":"publisher","first-page":"10525","DOI":"10.1073\/pnas.1903316116","volume":"116","author":"J Meixiong","year":"2019","unstructured":"Meixiong J, Vasavda C, Snyder SH, Dong X. MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus. Proc Natl Acad Sci U S A. 2019;116(21):10525\u201330. https:\/\/doi.org\/10.1073\/pnas.1903316116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"603_CR111","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/heartjnl-2013-304163","volume":"99","author":"PP Rainer","year":"2013","unstructured":"Rainer PP, Primessnig U, Harenkamp S, Doleschal B, Wallner M, Fauler G, et al. Bile acids induce arrhythmias in human atrial myocardium--implications for altered serum bile acid composition in patients with atrial fibrillation. Heart (London, England). 2013;99(22):1685\u201392. https:\/\/doi.org\/10.1136\/heartjnl-2013-304163.","journal-title":"Heart (London, England)"},{"issue":"2","key":"603_CR112","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1042\/cs1030191","volume":"103","author":"J Gorelik","year":"2002","unstructured":"Gorelik J, Harding SE, Shevchuk AI, Koralage D, Lab M, De Swiet M, et al. Taurocholate induces changes in rat cardiomyocyte contraction and calcium dynamics. Clin Sci (Lond). 2002;103(2):191\u2013200. https:\/\/doi.org\/10.1042\/cs1030191.","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"603_CR113","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.taap.2009.11.013","volume":"243","author":"K Allen","year":"2010","unstructured":"Allen K, Kim ND, Moon JO, Copple BL. Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling. Toxicol Appl Pharmacol. 2010;243(1):63\u20137. https:\/\/doi.org\/10.1016\/j.taap.2009.11.013.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"603_CR114","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/s0002-9440(10)64043-6","volume":"158","author":"H Miyoshi","year":"2001","unstructured":"Miyoshi H, Rust C, Guicciardi ME, Gores GJ. NF-kappaB is activated in cholestasis and functions to reduce liver injury. Am J Pathol. 2001;158(3):967\u201375. https:\/\/doi.org\/10.1016\/s0002-9440(10)64043-6.","journal-title":"Am J Pathol"},{"issue":"5","key":"603_CR115","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.yjmcc.2005.07.014","volume":"39","author":"KG Rajesh","year":"2005","unstructured":"Rajesh KG, Suzuki R, Maeda H, Yamamoto M, Yutong X, Sasaguri S. Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K\/Akt dependent pathway. J Mol Cell Cardiol. 2005;39(5):766\u201376. https:\/\/doi.org\/10.1016\/j.yjmcc.2005.07.014.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"603_CR116","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1142\/s0192415x07004813","volume":"35","author":"AL Rivard","year":"2007","unstructured":"Rivard AL, Steer CJ, Kren BT, Rodrigues CMP, Castro RE, Bianco RW, et al. Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat. Am J Chin Med. 2007;35(2):279\u201395. https:\/\/doi.org\/10.1142\/s0192415x07004813.","journal-title":"Am J Chin Med"},{"issue":"21","key":"603_CR117","doi-asserted-by":"publisher","first-page":"14948","DOI":"10.1074\/jbc.m506710200","volume":"281","author":"S Jean-Louis","year":"2006","unstructured":"Jean-Louis S, Akare S, Ali MA, Mash EA, Meuillet E, Martinez JD. Deoxycholic acid induces intracellular signaling through membrane perturbations. J Biol Chem. 2006;281(21):14948\u201360. https:\/\/doi.org\/10.1074\/jbc.m506710200.","journal-title":"J Biol Chem"},{"key":"603_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2021.105987","volume":"214","author":"F Quilty","year":"2021","unstructured":"Quilty F, Freeley M, Gargan S, Gilmer J, Long A. Deoxycholic acid induces proinflammatory cytokine production by model oesophageal cells via lipid rafts. J Steroid Biochem Mol Biol. 2021;214:105987. https:\/\/doi.org\/10.1016\/j.jsbmb.2021.105987.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"603_CR119","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00210-020-01962-7","volume":"394","author":"J Gao","year":"2021","unstructured":"Gao J, Yuan G, Xu Z, Lan L, Xin W. Chenodeoxycholic and deoxycholic acids induced positive inotropic and negative chronotropic effects on rat heart. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(4):765\u201373. https:\/\/doi.org\/10.1007\/s00210-020-01962-7.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"5","key":"603_CR120","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s11596-014-1344-7","volume":"34","author":"H Gao","year":"2014","unstructured":"Gao H, Chen LJ, Luo QQ, Liu XX, Hu Y, Yu LL, et al. Effect of cholic acid on fetal cardiac myocytes in intrahepatic choliestasis of pregnancy. J Huazhong Univ Sci Technolog Med Sci. 2014;34(5):736\u20139. https:\/\/doi.org\/10.1007\/s11596-014-1344-7.","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"7","key":"603_CR121","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.bbalip.2016.04.006","volume":"1861","author":"SM Centuori","year":"2016","unstructured":"Centuori SM, Gomes CJ, Trujillo J, Borg J, Brownlee J, Putnam CW, et al. Deoxycholic acid mediates non-canonical EGFR-MAPK activation through the induction of calcium signaling in colon cancer cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2016;1861(7):663\u201370. https:\/\/doi.org\/10.1016\/j.bbalip.2016.04.006.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"2","key":"603_CR122","doi-asserted-by":"publisher","first-page":"H741","DOI":"10.1152\/ajpheart.01182.2005","volume":"291","author":"P Qin","year":"2006","unstructured":"Qin P, Tang X, Elloso MM, Harnish DC. Bile acids induce adhesion molecule expression in endothelial cells through activation of reactive oxygen species, NF-kappaB, and p38. Am J Physiol Heart Circ Physiol. 2006;291(2):H741\u20137. https:\/\/doi.org\/10.1152\/ajpheart.01182.2005.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"603_CR123","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12012-010-9069-8","volume":"10","author":"JH Zavecz","year":"2010","unstructured":"Zavecz JH, Battarbee HD. The role of lipophilic bile acids in the development of cirrhotic cardiomyopathy. Cardiovasc Toxicol. 2010;10(2):117\u201329. https:\/\/doi.org\/10.1007\/s12012-010-9069-8.","journal-title":"Cardiovasc Toxicol"},{"issue":"12","key":"603_CR124","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/jphp.13169","volume":"71","author":"NB Bal","year":"2019","unstructured":"Bal NB, Han S, Kiremitci S, Sadi G, Uludag O, Demirel-Yilmaz E. Hypertension-induced cardiac impairment is reversed by the inhibition of endoplasmic reticulum stress. J Pharm Pharmacol. 2019;71(12):1809\u201321. https:\/\/doi.org\/10.1111\/jphp.13169.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"603_CR125","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000438616","volume":"38","author":"W Ding","year":"2016","unstructured":"Ding W, Wang B, Zhang M, Gu Y. Involvement of endoplasmic reticulum stress in uremic cardiomyopathy: protective effects of tauroursodeoxycholic acid. Cell Physiol Biochem. 2016;38(1):141\u201352. https:\/\/doi.org\/10.1159\/000438616.","journal-title":"Cell Physiol Biochem"},{"issue":"7","key":"603_CR126","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/j.1476-5381.2012.02117.x","volume":"167","author":"J Jehle","year":"2012","unstructured":"Jehle J, Staudacher I, Wiedmann F, Schweizer P, Becker R, Katus H, et al. Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid. Br J Pharmacol. 2012;167(7):1563\u201372. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.02117.x.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"603_CR127","doi-asserted-by":"publisher","first-page":"G1000","DOI":"10.1152\/ajpgi.00338.2003","volume":"286","author":"M M\u00fchlbauer","year":"2004","unstructured":"M\u00fchlbauer M, Allard B, Bosserhoff AK, Kiessling S, Herfarth H, Rogler G, et al. Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2004;286(6):G1000\u20138. https:\/\/doi.org\/10.1152\/ajpgi.00338.2003.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"10","key":"603_CR128","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1172\/jci21025","volume":"113","author":"M Watanabe","year":"2004","unstructured":"Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113(10):1408\u201318. https:\/\/doi.org\/10.1172\/jci21025.","journal-title":"J Clin Invest"},{"issue":"8","key":"603_CR129","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","volume":"33","author":"BL Clifford","year":"2021","unstructured":"Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, Jarrett KE, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021;33(8):1671-1684.e4. https:\/\/doi.org\/10.1016\/j.cmet.2021.06.012.","journal-title":"Cell Metab"},{"issue":"10","key":"603_CR130","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1210\/mend.15.10.0712","volume":"15","author":"HR Kast","year":"2001","unstructured":"Kast HR, Nguyen CM, Sinal CJ, Jones SA, Laffitte BA, Reue K, et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol. 2001;15(10):1720\u20138. https:\/\/doi.org\/10.1210\/mend.15.10.0712.","journal-title":"Mol Endocrinol"},{"issue":"2","key":"603_CR131","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/s0016-5085(03)00896-5","volume":"125","author":"T Claudel","year":"2003","unstructured":"Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003;125(2):544\u201355. https:\/\/doi.org\/10.1016\/s0016-5085(03)00896-5.","journal-title":"Gastroenterology"},{"issue":"13","key":"603_CR132","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1101\/gad.1083503","volume":"17","author":"JA Holt","year":"2003","unstructured":"Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17(13):1581\u201391. https:\/\/doi.org\/10.1101\/gad.1083503.","journal-title":"Genes Dev"},{"issue":"37","key":"603_CR133","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.m704165200","volume":"282","author":"H Kurosu","year":"2007","unstructured":"Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem. 2007;282(37):26687\u201395. https:\/\/doi.org\/10.1074\/jbc.m704165200.","journal-title":"J Biol Chem"},{"issue":"22","key":"603_CR134","doi-asserted-by":"publisher","first-page":"23158","DOI":"10.1074\/jbc.m314322200","volume":"279","author":"K Yamagata","year":"2004","unstructured":"Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem. 2004;279(22):23158\u201365. https:\/\/doi.org\/10.1074\/jbc.m314322200.","journal-title":"J Biol Chem"},{"issue":"17","key":"603_CR135","doi-asserted-by":"publisher","first-page":"11110","DOI":"10.1074\/jbc.m808747200","volume":"284","author":"DJ Shin","year":"2009","unstructured":"Shin DJ, Osborne TF. FGF15\/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J Biol Chem. 2009;284(17):11110\u201320. https:\/\/doi.org\/10.1074\/jbc.m808747200.","journal-title":"J Biol Chem"},{"issue":"3","key":"603_CR136","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cmet.2009.08.001","volume":"10","author":"C Thomas","year":"2009","unstructured":"Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167\u201377. https:\/\/doi.org\/10.1016\/j.cmet.2009.08.001.","journal-title":"Cell Metab"},{"issue":"1","key":"603_CR137","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/ncpendmet0017","volume":"1","author":"DJ Drucker","year":"2005","unstructured":"Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab. 2005;1(1):22\u201331. https:\/\/doi.org\/10.1038\/ncpendmet0017.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"825","key":"603_CR138","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado5177","volume":"17","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Huang H, Wang Y, Li X, Hou P, Yu M, et al. Intestinal TGR5-targeted carrier-drug conjugate improves glycemic control in mice and pigs. Sci Transl Med. 2025;17(825):eado5177. https:\/\/doi.org\/10.1126\/scitranslmed.ado5177.","journal-title":"Sci Transl Med"},{"issue":"7075","key":"603_CR139","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature04330","volume":"439","author":"M Watanabe","year":"2006","unstructured":"Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484\u20139. https:\/\/doi.org\/10.1038\/nature04330.","journal-title":"Nature"},{"issue":"3","key":"603_CR140","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.cmet.2015.07.002","volume":"22","author":"EPM Broeders","year":"2015","unstructured":"Broeders EPM, Nascimento EBM, Havekes B, Brans B, Roumans KHM, Tailleux A, et al. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. Cell Metab. 2015;22(3):418\u201326. https:\/\/doi.org\/10.1016\/j.cmet.2015.07.002.","journal-title":"Cell Metab"},{"issue":"26","key":"603_CR141","doi-asserted-by":"publisher","first-page":"10322","DOI":"10.1074\/jbc.ra118.002733","volume":"293","author":"T Sasaki","year":"2018","unstructured":"Sasaki T, Kuboyama A, Mita M, Murata S, Shimizu M, Inoue J, et al. The exercise-inducible bile acid receptor Tgr5 improves skeletal muscle function in mice. J Biol Chem. 2018;293(26):10322\u201332. https:\/\/doi.org\/10.1074\/jbc.ra118.002733.","journal-title":"J Biol Chem"},{"key":"603_CR142","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.coph.2020.04.008","volume":"53","author":"S Fiorucci","year":"2020","unstructured":"Fiorucci S, Baldoni M, Ricci P, Zampella A, Distrutti E, Biagioli M. Bile acid-activated receptors and the regulation of macrophages function in metabolic disorders. Curr Opin Pharmacol. 2020;53:45\u201354. https:\/\/doi.org\/10.1016\/j.coph.2020.04.008.","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"603_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.livres.2025.01.005","volume":"9","author":"S Fiorucci","year":"2025","unstructured":"Fiorucci S, Marchian\u00f2 S, Distrutti E, Biagioli M. Bile acids and their receptors in hepatic immunity. Liver Res. 2025;9(1):1\u201316. https:\/\/doi.org\/10.1016\/j.livres.2025.01.005.","journal-title":"Liver Res"},{"issue":"4","key":"603_CR144","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.cmet.2017.03.007","volume":"25","author":"H Hao","year":"2017","unstructured":"Hao H, Cao L, Jiang C, Che Y, Zhang S, Takahashi S, et al. Farnesoid X receptor regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis. Cell Metab. 2017;25(4):856-867.e5. https:\/\/doi.org\/10.1016\/j.cmet.2017.03.007.","journal-title":"Cell Metab"},{"issue":"6","key":"603_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167266","volume":"1870","author":"L Zhuang","year":"2024","unstructured":"Zhuang L, Jia N, Zhang L, Zhang Q, Antwi SO, Sartorius K, et al. Gpbar-1\/cAMP\/PKA signaling mitigates macrophage-mediated acute cholestatic liver injury via antagonizing NLRP3-ASC inflammasome. Biochim Biophys Acta Mol Basis Dis. 2024;1870(6):167266. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167266.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"4","key":"603_CR146","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","volume":"45","author":"C Guo","year":"2016","unstructured":"Guo C, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity. 2016;45(4):802\u201316. https:\/\/doi.org\/10.1016\/j.immuni.2016.09.008.","journal-title":"Immunity"},{"issue":"12","key":"603_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109726","volume":"36","author":"J Hu","year":"2021","unstructured":"Hu J, Wang C, Huang X, Yi S, Pan S, Zhang Y, et al. Gut microbiota-mediated secondary bile acids regulate dendritic cells to attenuate autoimmune uveitis through TGR5 signaling. Cell Rep. 2021;36(12):109726. https:\/\/doi.org\/10.1016\/j.celrep.2021.109726.","journal-title":"Cell Rep"},{"issue":"7785","key":"603_CR148","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-019-1785-z","volume":"576","author":"S Hang","year":"2019","unstructured":"Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019;576(7785):143\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1785-z.","journal-title":"Nature"},{"issue":"7790","key":"603_CR149","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-019-1865-0","volume":"577","author":"X Song","year":"2020","unstructured":"Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, et al. Microbial bile acid metabolites modulate gut ROR\u03b3+ regulatory T cell homeostasis. Nature. 2020;577(7790):410\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1865-0.","journal-title":"Nature"},{"issue":"7809","key":"603_CR150","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41586-020-2193-0","volume":"581","author":"C Campbell","year":"2020","unstructured":"Campbell C, McKenney PT, Konstantinovsky D, Isaeva OI, Schizas M, Verter J, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature. 2020;581(7809):475\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2193-0.","journal-title":"Nature"},{"issue":"1","key":"603_CR151","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.gastro.2012.09.055","volume":"144","author":"F Alemi","year":"2013","unstructured":"Alemi F, Poole DP, Chiu J, Schoonjans K, Cattaruzza F, Grider JR, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology. 2013;144(1):145\u201354. https:\/\/doi.org\/10.1053\/j.gastro.2012.09.055.","journal-title":"Gastroenterology"},{"issue":"6","key":"603_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102508","volume":"24","author":"N Li","year":"2021","unstructured":"Li N, Koester ST, Lachance DM, Dutta M, Cui JY, Dey N. Microbiome-encoded bile acid metabolism modulates colonic transit times. iScience. 2021;24(6):102508. https:\/\/doi.org\/10.1016\/j.isci.2021.102508.","journal-title":"iScience"},{"issue":"3","key":"603_CR153","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1053\/j.gastro.2020.05.067","volume":"159","author":"G Sorrentino","year":"2020","unstructured":"Sorrentino G, Perino A, Yildiz E, El Alam G, Bou Sleiman M, Gioiello A, et al. Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration. Gastroenterology. 2020;159(3):956-968.e8. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.067.","journal-title":"Gastroenterology"},{"issue":"8","key":"603_CR154","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41401-023-01081-y","volume":"44","author":"W Yang","year":"2023","unstructured":"Yang W, Han F, Gu Y, Qu H, Liu J, Shen J, et al. TGR5 agonist inhibits intestinal epithelial cell apoptosis via cAMP\/PKA\/c-FLIP\/JNK signaling pathway and ameliorates dextran sulfate sodium-induced ulcerative colitis. Acta Pharmacol Sin. 2023;44(8):1649\u201364. https:\/\/doi.org\/10.1038\/s41401-023-01081-y.","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"603_CR155","doi-asserted-by":"publisher","first-page":"G313","DOI":"10.1152\/ajpgi.00223.2024","volume":"329","author":"Y Cai","year":"2025","unstructured":"Cai Y, Chen X, Wang H, Hou L, Zheng R, Wang Y, et al. Investigating intestinal farnesoid X receptor functions at the intestinal mucosal barrier and in the intestinal microbiota in a biliary obstruction mouse model. Am J Physiol Gastrointest Liver Physiol. 2025;329(2):G313\u201327. https:\/\/doi.org\/10.1152\/ajpgi.00223.2024.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"603_CR156","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.chom.2023.12.015","volume":"32","author":"T Li","year":"2024","unstructured":"Li T, Ding N, Guo H, Hua R, Lin Z, Tian H, et al. A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage. Cell Host Microbe. 2024;32(2):191-208.e9. https:\/\/doi.org\/10.1016\/j.chom.2023.12.015.","journal-title":"Cell Host Microbe"},{"issue":"5","key":"603_CR157","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2019.01.036","volume":"176","author":"T Fu","year":"2019","unstructured":"Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, et al. FXR regulates intestinal cancer stem cell proliferation. Cell. 2019;176(5):1098-1112.e18. https:\/\/doi.org\/10.1016\/j.cell.2019.01.036.","journal-title":"Cell"},{"issue":"17","key":"603_CR158","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.3390\/ijms25179279","volume":"25","author":"L Romero-Ram\u00edrez","year":"2024","unstructured":"Romero-Ram\u00edrez L, Mey J. Emerging roles of bile acids and TGR5 in the central nervous system: molecular functions and therapeutic implications. Int J Mol Sci. 2024;25(17):9279. https:\/\/doi.org\/10.3390\/ijms25179279.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"603_CR159","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.neuron.2024.02.019","volume":"112","author":"XY Li","year":"2024","unstructured":"Li XY, Zhang SY, Hong YZ, Chen ZG, Long Y, Yuan DH, et al. TGR5-mediated lateral hypothalamus-dCA3-dorsolateral septum circuit regulates depressive-like behavior in male mice. Neuron. 2024;112(11):1795-1814.e10. https:\/\/doi.org\/10.1016\/j.neuron.2024.02.019.","journal-title":"Neuron"},{"key":"603_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107564","volume":"211","author":"AG Darmanto","year":"2025","unstructured":"Darmanto AG, Yen TL, Jan JS, Linh TTD, Taliyan R, Yang CH, et al. Beyond metabolic messengers: bile acids and TGR5 as pharmacotherapeutic intervention for psychiatric disorders. Pharmacol Res. 2025;211:107564. https:\/\/doi.org\/10.1016\/j.phrs.2024.107564.","journal-title":"Pharmacol Res"},{"issue":"10","key":"603_CR161","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/jbmr.1961","volume":"28","author":"SW Cho","year":"2013","unstructured":"Cho SW, An JH, Park H, Yang JY, Choi HJ, Kim SW, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013;28(10):2109\u201321. https:\/\/doi.org\/10.1002\/jbmr.1961.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"603_CR162","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3724\/abbs.2022201","volume":"55","author":"L Sun","year":"2023","unstructured":"Sun L, Li F, Tan W, Zhao W, Li Y, Zhu X, et al. Lithocholic acid promotes skeletal muscle regeneration through the TGR5 receptor. Acta Biochim Biophys Sin. 2023;55(1):51\u201361. https:\/\/doi.org\/10.3724\/abbs.2022201.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"6","key":"603_CR163","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1073\/pnas.1323977111","volume":"111","author":"X Zhang","year":"2014","unstructured":"Zhang X, Huang S, Gao M, Liu J, Jia X, Han Q, et al. Farnesoid X receptor (FXR) gene deficiency impairs urine concentration in mice. Proc Natl Acad Sci U S A. 2014;111(6):2277\u201382. https:\/\/doi.org\/10.1073\/pnas.1323977111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"603_CR164","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000538107","volume":"10","author":"Y Guo","year":"2024","unstructured":"Guo Y, Qiao R, Xie G, Yao Y, Du C, Shao Y, et al. Activation of TGR5 increases urine concentration by inducing AQP2 and AQP3 expression in renal medullary collecting ducts. Kidney Dis. 2024;10(3):181\u201392. https:\/\/doi.org\/10.1159\/000538107.","journal-title":"Kidney Dis"},{"issue":"1","key":"603_CR165","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13578-023-01035-1","volume":"13","author":"J Zeng","year":"2023","unstructured":"Zeng J, Fan J, Zhou H. Bile acid-mediated signaling in cholestatic liver diseases. Cell Biosci. 2023;13(1):77. https:\/\/doi.org\/10.1186\/s13578-023-01035-1.","journal-title":"Cell Biosci"},{"key":"603_CR166","doi-asserted-by":"publisher","first-page":"154","DOI":"10.37349\/edd.2022.00011","volume":"1","author":"G Merlen","year":"2022","unstructured":"Merlen G, Bidault-Jourdainne V, Doignon I, Garcin I, Tordjmann T. The bile acid receptor TGR5 and cholestasis. Explor Dig Dis. 2022;1:154\u201369. https:\/\/doi.org\/10.37349\/edd.2022.00011.","journal-title":"Explor Dig Dis"},{"issue":"9","key":"603_CR167","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/s2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361. https:\/\/doi.org\/10.1016\/s2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"603_CR168","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347. https:\/\/doi.org\/10.1097\/hep.0000000000000004.","journal-title":"Hepatology"},{"issue":"5","key":"603_CR169","doi-asserted-by":"publisher","first-page":"E644","DOI":"10.1152\/ajpendo.00346.2024","volume":"329","author":"M Pradeau","year":"2025","unstructured":"Pradeau M, Beaulieu S, Paquet V, Trottier J, Verreault M, Ferland S, et al. Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis. Am J Physiol Endocrinol Metab. 2025;329(5):E644\u201354. https:\/\/doi.org\/10.1152\/ajpendo.00346.2024.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"603_CR170","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s43066-024-00378-9","volume":"14","author":"AA Basuni","year":"2024","unstructured":"Basuni AA, Sweed D, Elgazzar MF, Khalil A. Exploring serum bile acids as potential noninvasive biomarkers for nonalcoholic fatty liver disease. Egypt Liver J. 2024;14(1):70. https:\/\/doi.org\/10.1186\/s43066-024-00378-9.","journal-title":"Egypt Liver J"},{"issue":"2","key":"603_CR171","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.mpg.0000170600.80640.88","volume":"41","author":"RJ Sokol","year":"2005","unstructured":"Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Kobak GE, Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J Pediatr Gastroenterol Nutr. 2005;41(2):235\u201343. https:\/\/doi.org\/10.1097\/01.mpg.0000170600.80640.88.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"603_CR172","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3164\/jcbn.13-46","volume":"54","author":"T Adachi","year":"2014","unstructured":"Adachi T, Kaminaga T, Yasuda H, Kamiya T, Hara H. The involvement of endoplasmic reticulum stress in bile acid-induced hepatocellular injury. J Clin Biochem Nutr. 2014;54(2):129\u201335. https:\/\/doi.org\/10.3164\/jcbn.13-46.","journal-title":"J Clin Biochem Nutr"},{"issue":"1","key":"603_CR173","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12964-025-02249-1","volume":"23","author":"RR Miao","year":"2025","unstructured":"Miao RR, Tan MY, Shao HB, Sun ZM, Zhan S, Liang WS, et al. Conjugated bile acids promote metabolic dysfunction-associated steatotic liver disease through inducing nuclear translocation of sphingosine-1-phosphate receptor 2 to disrupt peroxisome proliferator-activated receptor alpha. Cell Commun Signal. 2025;23(1):240. https:\/\/doi.org\/10.1186\/s12964-025-02249-1.","journal-title":"Cell Commun Signal"},{"issue":"2","key":"603_CR174","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jhep.2018.03.031","volume":"69","author":"K Brandl","year":"2018","unstructured":"Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018;69(2):396\u2013405. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.031.","journal-title":"J Hepatol"},{"issue":"11","key":"603_CR175","doi-asserted-by":"publisher","first-page":"G929","DOI":"10.1152\/ajpgi.00315.2013","volume":"306","author":"G Kakiyama","year":"2014","unstructured":"Kakiyama G, Hylemon PB, Zhou H, Pandak WM, Heuman DM, Kang DJ, et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2014;306(11):G929\u201337. https:\/\/doi.org\/10.1152\/ajpgi.00315.2013.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7","key":"603_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101848","volume":"8","author":"MI Keller","year":"2026","unstructured":"Keller MI, de Zawadzki A, Thiele M, Suvitaival T, Sulek K, Kuhn M, et al. Alcohol-related liver disease disrupts bile acid homeostasis and gut microbial bile acid metabolism. JHEP Rep. 2026;8(7):101848. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101848.","journal-title":"JHEP Rep"},{"issue":"9","key":"603_CR177","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41374-020-0439-y","volume":"100","author":"M Huang","year":"2020","unstructured":"Huang M, Kong B, Zhang M, Rizzolo D, Armstrong LE, Schumacher JD, et al. Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency. Lab Invest. 2020;100(9):1158\u201368. https:\/\/doi.org\/10.1038\/s41374-020-0439-y.","journal-title":"Lab Invest"},{"issue":"1","key":"603_CR178","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12072-023-10621-x","volume":"18","author":"L Li","year":"2024","unstructured":"Li L, Kong L, Xu S, Wang C, Gu J, Luo H, et al. FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease. Hepatol Int. 2024;18(1):188\u2013205. https:\/\/doi.org\/10.1007\/s12072-023-10621-x.","journal-title":"Hepatol Int"},{"issue":"11","key":"603_CR179","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/hep4.1256","volume":"2","author":"A Iracheta-Vellve","year":"2018","unstructured":"Iracheta-Vellve A, Calenda CD, Petrasek J, Ambade A, Kodys K, Adorini L, et al. FXR and TGR5 agonists ameliorate liver injury, steatosis, and inflammation after binge or prolonged alcohol feeding in mice. Hepatol Commun. 2018;2(11):1379\u201391. https:\/\/doi.org\/10.1002\/hep4.1256.","journal-title":"Hepatol Commun"},{"issue":"3","key":"603_CR180","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jcmgh.2021.12.001","volume":"13","author":"M Fan","year":"2022","unstructured":"Fan M, Wang Y, Jin L, Fang Z, Peng J, Tu J, et al. Bile acid-mediated activation of brown fat protects from alcohol-induced steatosis and liver injury in mice. Cell Mol Gastroenterol Hepatol. 2022;13(3):809\u201326. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.12.001.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"2","key":"603_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100230","volume":"3","author":"M Spatz","year":"2021","unstructured":"Spatz M, Ciocan D, Merlen G, Rainteau D, Humbert L, Gomes-Rochette N, et al. Bile acid-receptor TGR5 deficiency worsens liver injury in alcohol-fed mice by inducing intestinal microbiota dysbiosis. JHEP Rep. 2021;3(2):100230. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100230.","journal-title":"JHEP Rep"},{"issue":"12","key":"603_CR182","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1007\/s00432-020-03374-9","volume":"146","author":"PT Nguyen","year":"2020","unstructured":"Nguyen PT, Kanno K, Pham QT, Kikuchi Y, Kakimoto M, Kobayashi T, et al. Senescent hepatic stellate cells caused by deoxycholic acid modulates malignant behavior of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2020;146(12):3255\u201368. https:\/\/doi.org\/10.1007\/s00432-020-03374-9.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7456","key":"603_CR183","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature12347","volume":"499","author":"S Yoshimoto","year":"2013","unstructured":"Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97\u2013101. https:\/\/doi.org\/10.1038\/nature12347.","journal-title":"Nature"},{"issue":"1","key":"603_CR184","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s1000-1948(12)60001-x","volume":"27","author":"WY Zhang","year":"2012","unstructured":"Zhang WY, Chen P, Zhao YY, Lou GY. Farnesoid X receptor expression is reduced in human hepatocellular carcinoma. J Med Coll PLA. 2012;27(1):1\u20139. https:\/\/doi.org\/10.1016\/s1000-1948(12)60001-x.","journal-title":"J Med Coll PLA"},{"issue":"3","key":"603_CR185","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1158\/0008-5472.can-06-1078","volume":"67","author":"F Yang","year":"2007","unstructured":"Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67(3):863\u20137. https:\/\/doi.org\/10.1158\/0008-5472.can-06-1078.","journal-title":"Cancer Res"},{"issue":"1","key":"603_CR186","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/jpet.111.179390","volume":"338","author":"A Wolfe","year":"2011","unstructured":"Wolfe A, Thomas A, Edwards G, Jaseja R, Guo GL, Apte U. Increased activation of the Wnt\/\u03b2-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther. 2011;338(1):12\u201321. https:\/\/doi.org\/10.1124\/jpet.111.179390.","journal-title":"J Pharmacol Exp Ther"},{"key":"603_CR187","doi-asserted-by":"publisher","first-page":"1113785","DOI":"10.3389\/fonc.2022.1113785","volume":"12","author":"N Chen","year":"2023","unstructured":"Chen N, Wang J, Zhou L, Hu B, Chen Y, Zhu Z. GPBAR1 is associated with asynchronous bone metastasis and poor prognosis of hepatocellular carcinoma. Front Oncol. 2023;12:1113785. https:\/\/doi.org\/10.3389\/fonc.2022.1113785.","journal-title":"Front Oncol"},{"issue":"6391","key":"603_CR188","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5931","volume":"360","author":"C Ma","year":"2018","unstructured":"Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360(6391):eaan5931. https:\/\/doi.org\/10.1126\/science.aan5931.","journal-title":"Science"},{"issue":"5","key":"603_CR189","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jhep.2025.12.029","volume":"84","author":"K Xu","year":"2026","unstructured":"Xu K, Dong X, Qu H, Hu J, Jiao J, Chen R, et al. AF6 knockout-induced upregulation of bile acid production promotes CXCL14-mediated antitumor immunity in HCC. J Hepatol. 2026;84(5):976\u201392. https:\/\/doi.org\/10.1016\/j.jhep.2025.12.029.","journal-title":"J Hepatol"},{"issue":"23","key":"603_CR190","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000038457","volume":"103","author":"RH Xu","year":"2024","unstructured":"Xu RH, Shen JN, Lu JB, Liu YJ, Song Y, Cao Y, et al. Bile acid profiles and classification model accuracy for inflammatory bowel disease diagnosis. Medicine. 2024;103(23):e38457. https:\/\/doi.org\/10.1097\/md.0000000000038457.","journal-title":"Medicine"},{"issue":"1","key":"603_CR191","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae125","volume":"19","author":"S Jangi","year":"2025","unstructured":"Jangi S, Zhao N, Hsia K, Park YS, Michaud DS, Yoon H. Specific bacterial co-abundance groups are associated with inflammatory status in patients with ulcerative colitis. J Crohns Colitis. 2025;19(1):jjae125. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae125.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"603_CR192","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/cells10061281","volume":"10","author":"M Biagioli","year":"2021","unstructured":"Biagioli M, Marchian\u00f2 S, Carino A, Di Giorgio C, Santucci L, Distrutti E, et al. Bile acids activated receptors in inflammatory bowel disease. Cells. 2021;10(6):1281. https:\/\/doi.org\/10.3390\/cells10061281.","journal-title":"Cells"},{"issue":"2","key":"603_CR193","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1172\/jci105722","volume":"47","author":"WE Meihoff","year":"1968","unstructured":"Meihoff WE, Kern F. Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. J Clin Invest. 1968;47(2):261\u20137. https:\/\/doi.org\/10.1172\/jci105722.","journal-title":"J Clin Invest"},{"issue":"2","key":"603_CR194","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/ecco-jcc\/jju022","volume":"9","author":"JD Nolan","year":"2015","unstructured":"Nolan JD, Johnston IM, Pattni SS, Dew T, Orchard TR, Walters JR. Diarrhea in Crohn\u2019s disease: investigating the role of the ileal hormone fibroblast growth factor 19. J Crohns Colitis. 2015;9(2):125\u201331. https:\/\/doi.org\/10.1093\/ecco-jcc\/jju022.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"603_CR195","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12944-023-01971-4","volume":"22","author":"S Sommersberger","year":"2023","unstructured":"Sommersberger S, Gunawan S, Elger T, Fererberger T, Loibl J, Huss M, et al. Altered fecal bile acid composition in active ulcerative colitis. Lipids Health Dis. 2023;22(1):199. https:\/\/doi.org\/10.1186\/s12944-023-01971-4.","journal-title":"Lipids Health Dis"},{"issue":"8","key":"603_CR196","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023745","volume":"6","author":"RM Nijmeijer","year":"2011","unstructured":"Nijmeijer RM, Gadaleta RM, van Mil SWC, van Bodegraven AA, Crusius JBA, Dijkstra G, et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS ONE. 2011;6(8):e23745. https:\/\/doi.org\/10.1371\/journal.pone.0023745.","journal-title":"PLoS ONE"},{"issue":"10","key":"603_CR197","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025637","volume":"6","author":"S Cipriani","year":"2011","unstructured":"Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE. 2011;6(10):e25637. https:\/\/doi.org\/10.1371\/journal.pone.0025637.","journal-title":"PLoS ONE"},{"issue":"9","key":"603_CR198","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1172\/jci65842","volume":"123","author":"W Liu","year":"2013","unstructured":"Liu W, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U, et al. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013;123(9):3983\u201396. https:\/\/doi.org\/10.1172\/jci65842.","journal-title":"J Clin Invest"},{"issue":"3","key":"603_CR199","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/s0300-5089(21)00739-2","volume":"15","author":"H Fromm","year":"1986","unstructured":"Fromm H, Malavolti M. Bile acid-induced diarrhoea. Clin Gastroenterol. 1986;15(3):567\u201382. https:\/\/doi.org\/10.1016\/s0300-5089(21)00739-2.","journal-title":"Clin Gastroenterol"},{"issue":"11","key":"603_CR200","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cgh.2009.04.024","volume":"7","author":"JRF Walters","year":"2009","unstructured":"Walters JRF, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009;7(11):1189\u201394. https:\/\/doi.org\/10.1016\/j.cgh.2009.04.024.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"603_CR201","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/apt.12466","volume":"38","author":"SS Pattni","year":"2013","unstructured":"Pattni SS, Brydon WG, Dew T, Johnston IM, Nolan JD, Srinivas M, et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther. 2013;38(8):967\u201376. https:\/\/doi.org\/10.1111\/apt.12466.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"603_CR202","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s10620-021-07042-x","volume":"67","author":"C Chang","year":"2022","unstructured":"Chang C, Jiang J, Sun R, Wang S, Chen H. Downregulation of serum and distal ileum fibroblast growth Factor19 in bile acid diarrhoea patients. Dig Dis Sci. 2022;67(3):872\u20139. https:\/\/doi.org\/10.1007\/s10620-021-07042-x.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"603_CR203","doi-asserted-by":"publisher","first-page":"20436","DOI":"10.1038\/s41598-020-77374-7","volume":"10","author":"NM Sagar","year":"2020","unstructured":"Sagar NM, Duboc H, Kay GL, Alam MT, Wicaksono AN, Covington JA, et al. The pathophysiology of bile acid diarrhoea: differences in the colonic microbiome, metabolome and bile acids. Sci Rep. 2020;10(1):20436. https:\/\/doi.org\/10.1038\/s41598-020-77374-7.","journal-title":"Sci Rep"},{"issue":"1","key":"603_CR204","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1172\/jci130976","volume":"130","author":"L Zhao","year":"2020","unstructured":"Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 2020;130(1):438\u201350. https:\/\/doi.org\/10.1172\/jci130976.","journal-title":"J Clin Invest"},{"issue":"2","key":"603_CR205","doi-asserted-by":"publisher","first-page":"G110","DOI":"10.1152\/ajpgi.00341.2025","volume":"330","author":"CE Curley","year":"2026","unstructured":"Curley CE, Mobbs CL, Mroz MS, McLean MH, Keely SJ. The secondary bile acid, lithocholic acid, inhibits cystic fibrosis transmembrane conductance regulator expression and activity in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2026;330(2):G110\u201322. https:\/\/doi.org\/10.1152\/ajpgi.00341.2025.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"603_CR206","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/molecules27030723","volume":"27","author":"H Zeng","year":"2022","unstructured":"Zeng H, Safratowich BD, Cheng WH, Larson KJ, Briske-Anderson M. Deoxycholic acid modulates cell-junction gene expression and increases intestinal barrier dysfunction. Molecules. 2022;27(3):723. https:\/\/doi.org\/10.3390\/molecules27030723.","journal-title":"Molecules"},{"issue":"5","key":"603_CR207","doi-asserted-by":"publisher","first-page":"G480","DOI":"10.1152\/ajpgi.00011.2022","volume":"322","author":"M Camilleri","year":"2022","unstructured":"Camilleri M. Bile acid detergency: permeability, inflammation, and effects of sulfation. Am J Physiol Gastrointest Liver Physiol. 2022;322(5):G480\u20138. https:\/\/doi.org\/10.1152\/ajpgi.00011.2022.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"603_CR208","doi-asserted-by":"publisher","first-page":"29413","DOI":"10.1038\/s41598-025-15159-6","volume":"15","author":"SM Lee","year":"2025","unstructured":"Lee SM, Park SY, Sophallika K, Chung JO, Jung YW, Kim DH, et al. Dysregulation of bile acid metabolism in patients with colorectal cancer. Sci Rep. 2025;15(1):29413. https:\/\/doi.org\/10.1038\/s41598-025-15159-6.","journal-title":"Sci Rep"},{"issue":"1","key":"603_CR209","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41598-024-84801-6","volume":"15","author":"S Yang","year":"2025","unstructured":"Yang S, Wang Y, Sheng L, Cui W, Ma C. The effect of fecal bile acids on the incidence and risk-stratification of colorectal cancer: an updated systematic review and meta-analysis. Sci Rep. 2025;15(1):740. https:\/\/doi.org\/10.1038\/s41598-024-84801-6.","journal-title":"Sci Rep"},{"issue":"4","key":"603_CR210","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.immuni.2024.02.014","volume":"57","author":"J Cong","year":"2024","unstructured":"Cong J, Liu P, Han Z, Ying W, Li C, Yang Y, et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions. Immunity. 2024;57(4):876-889.e11. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.014.","journal-title":"Immunity"},{"issue":"1","key":"603_CR211","doi-asserted-by":"publisher","first-page":"G48","DOI":"10.1152\/ajpgi.00234.2013","volume":"306","author":"AM Bailey","year":"2014","unstructured":"Bailey AM, Zhan L, Maru D, Shureiqi I, Pickering CR, Kiriakova G, et al. FXR silencing in human colon cancer by DNA methylation and KRAS signaling. Am J Physiol Gastrointest Liver Physiol. 2014;306(1):G48\u201358. https:\/\/doi.org\/10.1152\/ajpgi.00234.2013.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"603_CR212","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41420-021-00589-8","volume":"7","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xu H, Zhang C, Tang Q, Bi F. Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis. Cell Death Discov. 2021;7(1):207. https:\/\/doi.org\/10.1038\/s41420-021-00589-8.","journal-title":"Cell Death Discov"},{"issue":"1","key":"603_CR213","doi-asserted-by":"publisher","first-page":"24285","DOI":"10.1038\/s41598-024-75516-9","volume":"14","author":"A Fathima","year":"2024","unstructured":"Fathima A, Jamma T. UDCA ameliorates inflammation driven EMT by inducing TGR5 dependent SOCS1 expression in mouse macrophages. Sci Rep. 2024;14(1):24285. https:\/\/doi.org\/10.1038\/s41598-024-75516-9.","journal-title":"Sci Rep"},{"issue":"6","key":"603_CR214","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13577-025-01304-w","volume":"38","author":"H Zhao","year":"2025","unstructured":"Zhao H, Yang F, Yang J, Yang S. Multifaceted roles of microbiota-derived deoxycholic acid in gastrointestinal cancers: from barrier disruption to therapeutic implications. Hum Cell. 2025;38(6):176. https:\/\/doi.org\/10.1007\/s13577-025-01304-w.","journal-title":"Hum Cell"},{"issue":"1","key":"603_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38778-2","volume":"9","author":"TT Nguyen","year":"2019","unstructured":"Nguyen TT, Ung TT, Li S, Lian S, Xia Y, Park SY, et al. Metformin inhibits lithocholic acid-induced interleukin 8 upregulation in colorectal cancer cells by suppressing ROS production and NF-kB activity. Sci Rep. 2019;9(1):2003. https:\/\/doi.org\/10.1038\/s41598-019-38778-2.","journal-title":"Sci Rep"},{"issue":"1","key":"603_CR216","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2009.08.030","volume":"290","author":"MK Baek","year":"2010","unstructured":"Baek MK, Park JS, Park JH, Kim MH, Kim HD, Bae WK, et al. Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. Cancer Lett. 2010;290(1):123\u20138. https:\/\/doi.org\/10.1016\/j.canlet.2009.08.030.","journal-title":"Cancer Lett"},{"issue":"10","key":"603_CR217","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.3390\/ijms21103420","volume":"21","author":"S Li","year":"2020","unstructured":"Li S, Ung TT, Nguyen TT, Sah DK, Park SY, Jung YD. Cholic acid stimulates MMP-9 in human colon cancer cells via activation of MAPK, AP-1, and NF-\u03baB activity. Int J Mol Sci. 2020;21(10):3420. https:\/\/doi.org\/10.3390\/ijms21103420.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"603_CR218","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41467-025-67268-5","volume":"17","author":"JJ Noubiap","year":"2026","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF, Ndoadoumgue AL, Ngouo AT, Tounouga DN, et al. Worldwide trends in metabolic syndrome from 2000 to 2023: a systematic review and modelling analysis. Nat Commun. 2026;17(1):573. https:\/\/doi.org\/10.1038\/s41467-025-67268-5.","journal-title":"Nat Commun"},{"issue":"4","key":"603_CR219","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/hep.29857","volume":"68","author":"P Pathak","year":"2018","unstructured":"Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, et al. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism. Hepatology. 2018;68(4):1574\u201388. https:\/\/doi.org\/10.1002\/hep.29857.","journal-title":"Hepatology"},{"issue":"1","key":"603_CR220","doi-asserted-by":"publisher","first-page":"10166","DOI":"10.1038\/ncomms10166","volume":"6","author":"C Jiang","year":"2015","unstructured":"Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015;6(1):10166. https:\/\/doi.org\/10.1038\/ncomms10166.","journal-title":"Nat Commun"},{"issue":"5","key":"603_CR221","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","volume":"151","author":"FJ Gonzalez","year":"2016","unstructured":"Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology. 2016;151(5):845\u201359. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.057.","journal-title":"Gastroenterology"},{"issue":"12","key":"603_CR222","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1002\/hep4.2099","volume":"6","author":"J Jiang","year":"2022","unstructured":"Jiang J, Ma Y, Liu Y, Lu D, Gao X, Krausz KW, et al. Glycine-\u03b2-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice. Hepatol Commun. 2022;6(12):3363\u201378. https:\/\/doi.org\/10.1002\/hep4.2099.","journal-title":"Hepatol Commun"},{"issue":"14","key":"603_CR223","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.3390\/ijms26146547","volume":"26","author":"L Zangerolamo","year":"2025","unstructured":"Zangerolamo L, Carvalho M, Barbosa HCL. The critical role of the bile acid receptor TGR5 in energy homeostasis: insights into physiology and therapeutic potential. Int J Mol Sci. 2025;26(14):6547. https:\/\/doi.org\/10.3390\/ijms26146547.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"603_CR224","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1172\/jci76289","volume":"124","author":"A Perino","year":"2014","unstructured":"Perino A, Pols TWH, Nomura M, Stein S, Pellicciari R, Schoonjans K. TGR5 reduces macrophage migration through mTOR-induced C\/EBP\u03b2 differential translation. J Clin Invest. 2014;124(12):5424\u201336. https:\/\/doi.org\/10.1172\/jci76289.","journal-title":"J Clin Invest"},{"issue":"1","key":"603_CR225","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41467-025-67172-y","volume":"17","author":"X Wang","year":"2026","unstructured":"Wang X, Wang X, Yu S, Huang L, Xue Q, Yang X, et al. Schisantherin A interacts with gut bacteria to stimulate adipose tissue thermogenesis in obese mice via a TGR5-p-CREB-STAT6 signaling pathway. Nat Commun. 2026;17(1):476. https:\/\/doi.org\/10.1038\/s41467-025-67172-y.","journal-title":"Nat Commun"},{"issue":"4","key":"603_CR226","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41574-024-01067-8","volume":"21","author":"M Cadena Sandoval","year":"2025","unstructured":"Cadena Sandoval M, Haeusler RA. Bile acid metabolism in type 2 diabetes mellitus. Nat Rev Endocrinol. 2025;21(4):203\u201313. https:\/\/doi.org\/10.1038\/s41574-024-01067-8.","journal-title":"Nat Rev Endocrinol"},{"key":"603_CR227","doi-asserted-by":"publisher","first-page":"1656942","DOI":"10.3389\/fendo.2025.1656942","volume":"16","author":"S Grossi","year":"2025","unstructured":"Grossi S, Giusti EM, Veronesi G, Delaiti S, Mancini A, Migliaccio L, et al. Circulating bile acids and HOMA-IR: cross-sectional results from the RoCAV population-based study. Front Endocrinol (Lausanne). 2025;16:1656942. https:\/\/doi.org\/10.3389\/fendo.2025.1656942.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"603_CR228","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1210\/jc.2016-1607","volume":"101","author":"DP Sonne","year":"2016","unstructured":"Sonne DP, van Nierop FS, Kulik W, Soeters MR, Vilsb\u00f8ll T, Knop FK. Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2016;101(8):3002\u20139. https:\/\/doi.org\/10.1210\/jc.2016-1607.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"603_CR229","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1210\/clinem\/dgae261","volume":"110","author":"HH Nerild","year":"2025","unstructured":"Nerild HH, Gilliam-Vigh H, Ellegaard AM, Forman JL, Vilsb\u00f8ll T, Sonne DP, et al. Expression of bile acid receptors and transporters along the intestine of patients with type 2 diabetes and controls. J Clin Endocrinol Metab. 2025;110(3):e660\u20136. https:\/\/doi.org\/10.1210\/clinem\/dgae261.","journal-title":"J Clin Endocrinol Metab"},{"key":"603_CR230","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102759","volume":"55","author":"G Calderon","year":"2020","unstructured":"Calderon G, McRae A, Rievaj J, Davis J, Zandvakili I, Linker-Nord S, et al. Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. EBioMedicine. 2020;55:102759. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102759.","journal-title":"EBioMedicine"},{"issue":"2","key":"603_CR231","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2337\/db18-0315","volume":"68","author":"J Maczewsky","year":"2019","unstructured":"Maczewsky J, Kaiser J, Gresch A, Gerst F, D\u00fcfer M, Krippeit-Drews P, et al. TGR5 activation promotes stimulus-secretion coupling of pancreatic \u03b2-Cells via a PKA-dependent pathway. Diabetes. 2019;68(2):324\u201336. https:\/\/doi.org\/10.2337\/db18-0315.","journal-title":"Diabetes"},{"issue":"6","key":"603_CR232","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1194\/jlr.m800619-jlr200","volume":"50","author":"HB Hartman","year":"2009","unstructured":"Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-\/- and apoE-\/- mice. J Lipid Res. 2009;50(6):1090\u2013100. https:\/\/doi.org\/10.1194\/jlr.m800619-jlr200.","journal-title":"J Lipid Res"},{"issue":"9","key":"603_CR233","doi-asserted-by":"publisher","DOI":"10.1172\/jci142865","volume":"131","author":"Q Wu","year":"2021","unstructured":"Wu Q, Sun L, Hu X, Wang X, Xu F, Chen B, et al. Suppressing the intestinal farnesoid X receptor\/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis. J Clin Invest. 2021;131(9):e142865. https:\/\/doi.org\/10.1172\/jci142865.","journal-title":"J Clin Invest"},{"issue":"6","key":"603_CR234","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.cmet.2011.11.006","volume":"14","author":"TWH Pols","year":"2011","unstructured":"Pols TWH, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14(6):747\u201357. https:\/\/doi.org\/10.1016\/j.cmet.2011.11.006.","journal-title":"Cell Metab"},{"issue":"7","key":"603_CR235","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1161\/atvbaha.113.301565","volume":"33","author":"T Kida","year":"2013","unstructured":"Kida T, Tsubosaka Y, Hori M, Ozaki H, Murata T. Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33(7):1663\u20139. https:\/\/doi.org\/10.1161\/atvbaha.113.301565.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"603_CR236","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108270","volume":"9","author":"S Miyazaki-Anzai","year":"2014","unstructured":"Miyazaki-Anzai S, Masuda M, Levi M, Keenan AL, Miyazaki M. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS ONE. 2014;9(9):e108270. https:\/\/doi.org\/10.1371\/journal.pone.0108270.","journal-title":"PLoS ONE"},{"issue":"9","key":"603_CR237","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1194\/jlr.m087239","volume":"59","author":"S Miyazaki-Anzai","year":"2018","unstructured":"Miyazaki-Anzai S, Masuda M, Kohno S, Levi M, Shiozaki Y, Keenan AL, et al. Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation. J Lipid Res. 2018;59(9):1709\u201313. https:\/\/doi.org\/10.1194\/jlr.m087239.","journal-title":"J Lipid Res"},{"issue":"1","key":"603_CR238","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cardiores.2007.05.016","volume":"76","author":"M Pennings","year":"2007","unstructured":"Pennings M, Hildebrand R, Ye D, Kunne C, Van Berkel T, Groen A, et al. Bone marrow-derived multidrug resistance protein ABCB4 protects against atherosclerotic lesion development in LDL receptor knockout mice. Cardiovasc Res. 2007;76(1):175\u201383. https:\/\/doi.org\/10.1016\/j.cardiores.2007.05.016.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"603_CR239","doi-asserted-by":"publisher","first-page":"151","DOI":"10.14218\/jcth.2023.00095","volume":"12","author":"T Liu","year":"2024","unstructured":"Liu T, Wang RX, Han J, Li ZD, Sheps JA, Zheng LJ, et al. Comprehensive bile acid profiling of ABCB4-mutated patients and the prognostic role of taurine-conjugated 3\u03b1,6\u03b1,7\u03b1,12\u03b1-tetrahydroxylated bile acid in cholestasis. J Clin Transl Hepatol. 2024;12(2):151\u201361. https:\/\/doi.org\/10.14218\/jcth.2023.00095.","journal-title":"J Clin Transl Hepatol"},{"key":"603_CR240","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/954781","volume":"2014","author":"SY Morita","year":"2014","unstructured":"Morita SY, Terada T. Molecular mechanisms for biliary phospholipid and drug efflux mediated by ABCB4 and bile salts. Biomed Res Int. 2014;2014:954781. https:\/\/doi.org\/10.1155\/2014\/954781.","journal-title":"Biomed Res Int"},{"issue":"16","key":"603_CR241","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.3390\/ijms26167905","volume":"26","author":"M Del Barrio","year":"2025","unstructured":"Del Barrio M, D\u00edaz-Gonz\u00e1lez \u00c1, Alonso-Pe\u00f1a M. Primary biliary cholangitis: immunopathogenesis and the role of bile acid metabolism in disease progression. Int J Mol Sci. 2025;26(16):7905. https:\/\/doi.org\/10.3390\/ijms26167905.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"603_CR242","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","volume":"18","author":"L Sun","year":"2021","unstructured":"Sun L, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat Rev Gastroenterol Hepatol. 2021;18(5):335\u201347. https:\/\/doi.org\/10.1038\/s41575-020-00404-2.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"603_CR243","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/s-0030-1253226","volume":"30","author":"C Soroka","year":"2010","unstructured":"Soroka C, Ballatori N, Boyer J. Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis. Semin Liver Dis. 2010;30(2):178\u201385. https:\/\/doi.org\/10.1055\/s-0030-1253226.","journal-title":"Semin Liver Dis"},{"key":"603_CR244","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115606","volume":"168","author":"D Xiang","year":"2023","unstructured":"Xiang D, Yang J, Liu L, Yu H, Gong X, Liu D. The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis. Biomed Pharmacother. 2023;168:115606. https:\/\/doi.org\/10.1016\/j.biopha.2023.115606.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"603_CR245","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/hep.25691","volume":"56","author":"JM Banales","year":"2012","unstructured":"Banales JM, S\u00e1ez E, \u00dariz M, Sarvide S, Urribarri AD, Splinter P, et al. Up-regulation of microRNA 506 leads to decreased Cl-\/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology. 2012;56(2):687\u201397. https:\/\/doi.org\/10.1002\/hep.25691.","journal-title":"Hepatology"},{"issue":"4","key":"603_CR246","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/hep.29533","volume":"67","author":"O Erice","year":"2018","unstructured":"Erice O, Munoz-Garrido P, Vaquero J, Perugorria MJ, Fernandez-Barrena MG, Saez E, et al. MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. Hepatology. 2018;67(4):1420\u201340. https:\/\/doi.org\/10.1002\/hep.29533.","journal-title":"Hepatology"},{"issue":"6","key":"603_CR247","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41374-018-0045-4","volume":"98","author":"M Sasaki","year":"2018","unstructured":"Sasaki M, Sato Y, Nakanuma Y. An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis. Lab Invest. 2018;98(6):745\u201354. https:\/\/doi.org\/10.1038\/s41374-018-0045-4.","journal-title":"Lab Invest"},{"issue":"1","key":"603_CR248","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jhep.2022.07.034","volume":"78","author":"L Kennedy","year":"2023","unstructured":"Kennedy L, Carpino G, Owen T, Ceci L, Kundu D, Meadows V, et al. Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes. J Hepatol. 2023;78(1):99\u2013113. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.034.","journal-title":"J Hepatol"},{"issue":"1","key":"603_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38840-8","volume":"14","author":"W Gui","year":"2023","unstructured":"Gui W, Hole MJ, Molinaro A, Edlund K, J\u00f8rgensen KK, Su H, et al. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis. Nat Commun. 2023;14(1):3304. https:\/\/doi.org\/10.1038\/s41467-023-38840-8.","journal-title":"Nat Commun"},{"issue":"1","key":"603_CR250","doi-asserted-by":"publisher","first-page":"39573","DOI":"10.1038\/srep39573","volume":"6","author":"M Milkiewicz","year":"2016","unstructured":"Milkiewicz M, Klak M, Kempinska-Podhorodecka A, Wiechowska-Kozlowska A, Urasinska E, Blatkiewicz M, et al. Impaired hepatic adaptation to chronic cholestasis induced by primary sclerosing cholangitis. Sci Rep. 2016;6(1):39573. https:\/\/doi.org\/10.1038\/srep39573.","journal-title":"Sci Rep"},{"issue":"1","key":"603_CR251","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12072-016-9769-7","volume":"11","author":"SJ Zweers","year":"2017","unstructured":"Zweers SJ, de Vries EM, Lenicek M, Tolenaars D, de Waart DR, Koelfat KVK, et al. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge. Hepatol Int. 2017;11(1):132\u201340. https:\/\/doi.org\/10.1007\/s12072-016-9769-7.","journal-title":"Hepatol Int"},{"issue":"11","key":"603_CR252","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100561","volume":"4","author":"PR Braadland","year":"2022","unstructured":"Braadland PR, Schneider KM, Bergquist A, Molinaro A, L\u00f6vgren-Sandblom A, Henricsson M, et al. Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis. JHEP Rep. 2022;4(11):100561. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100561.","journal-title":"JHEP Rep"},{"issue":"1","key":"603_CR253","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/s2468-1253(25)00208-0","volume":"11","author":"M Trauner","year":"2026","unstructured":"Trauner M, Levy C, Tanaka A, Goodman Z, Thorburn D, Joshi D, et al. Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):46\u201358. https:\/\/doi.org\/10.1016\/s2468-1253(25)00208-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"603_CR254","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jhep.2021.03.029","volume":"75","author":"M Reich","year":"2021","unstructured":"Reich M, Spomer L, Klindt C, Fuchs K, Stindt J, Deutschmann K, et al. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. J Hepatol. 2021;75(3):634\u201346. https:\/\/doi.org\/10.1016\/j.jhep.2021.03.029.","journal-title":"J Hepatol"},{"issue":"17","key":"603_CR255","doi-asserted-by":"publisher","DOI":"10.1172\/jci174218","volume":"133","author":"L V\u00e1ncza","year":"2023","unstructured":"V\u00e1ncza L, Torok NJ. Primary sclerosing cholangitis and the path to translation. J Clin Invest. 2023;133(17):e174218. https:\/\/doi.org\/10.1172\/jci174218.","journal-title":"J Clin Invest"},{"issue":"1","key":"603_CR256","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1186\/s12885-024-13081-0","volume":"24","author":"M Deng","year":"2024","unstructured":"Deng M, Liu J, Zhang L, Lou Y, Qiu Y. Identification of molecular subtypes based on bile acid metabolism in cholangiocarcinoma. BMC Cancer. 2024;24(1):1313. https:\/\/doi.org\/10.1186\/s12885-024-13081-0.","journal-title":"BMC Cancer"},{"issue":"12","key":"603_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101467","volume":"7","author":"Y Liu","year":"2025","unstructured":"Liu Y, Hassan H, Brooks TR, VanLith C, Cooley M, Elgozair M, et al. Blood and tissue dysregulated bile acids and short-chain fatty acids in cholangiocarcinoma. JHEP Rep. 2025;7(12):101467. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101467.","journal-title":"JHEP Rep"},{"issue":"8","key":"603_CR258","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","volume":"43","author":"F Huang","year":"2025","unstructured":"Huang F, Liu Z, Song Y, Wang G, Shi A, Chen T, et al. Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. Cancer Cell. 2025;43(8):1460-1475.e10. https:\/\/doi.org\/10.1016\/j.ccell.2025.05.017.","journal-title":"Cancer Cell"},{"issue":"1","key":"603_CR259","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000491715","volume":"48","author":"B Lv","year":"2018","unstructured":"Lv B, Ma L, Tang W, Huang P, Yang B, Wang L, et al. FXR acts as a metastasis suppressor in intrahepatic cholangiocarcinoma by inhibiting IL-6-Induced epithelial-mesenchymal transition. Cell Physiol Biochem. 2018;48(1):158\u201372. https:\/\/doi.org\/10.1159\/000491715.","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"603_CR260","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/hep.27085","volume":"60","author":"R Liu","year":"2014","unstructured":"Liu R, Zhao R, Zhou X, Liang X, Campbell DJW, Zhang X, et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology. 2014;60(3):908\u201318. https:\/\/doi.org\/10.1002\/hep.27085.","journal-title":"Hepatology"},{"issue":"4","key":"603_CR261","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/gast.2002.32410","volume":"122","author":"JH Yoon","year":"2002","unstructured":"Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002;122(4):985\u201393. https:\/\/doi.org\/10.1053\/gast.2002.32410.","journal-title":"Gastroenterology"},{"issue":"7","key":"603_CR262","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/nejmoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631\u201343. https:\/\/doi.org\/10.1056\/nejmoa1509840.","journal-title":"N Engl J Med"},{"key":"603_CR263","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122355","volume":"337","author":"Q Lu","year":"2024","unstructured":"Lu Q, Zhu Y, Wang C, Zhang R, Miao Y, Chai Y, et al. Obeticholic acid protects against lithocholic acid-induced exogenous cell apoptosis during cholestatic liver injury. Life Sci. 2024;337:122355. https:\/\/doi.org\/10.1016\/j.lfs.2023.122355.","journal-title":"Life Sci"},{"key":"603_CR264","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.dld.2023.01.056","volume":"55","author":"M Cagna","year":"2023","unstructured":"Cagna M, Palladini G, Croce AC, Adorini L, Ferrigno A, Vairetti M, et al. Obeticholic acid reduces lipid accumulation and fibrosis in a diet-induced ob\/ob mouse model of NASH. Dig Liver Dis. 2023;55:S30. https:\/\/doi.org\/10.1016\/j.dld.2023.01.056.","journal-title":"Dig Liver Dis"},{"issue":"24","key":"603_CR265","doi-asserted-by":"publisher","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","volume":"60","author":"DC Tully","year":"2017","unstructured":"Tully DC, Rucker PV, Chianelli D. Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem. 2017;60(24):9960\u201373. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00907.","journal-title":"J Med Chem"},{"issue":"8","key":"603_CR266","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/hep4.1368","volume":"3","author":"ED Hernandez","year":"2019","unstructured":"Hernandez ED, Zheng L, Kim Y, Fang B, Liu B, Valdez RA, et al. Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents. Hepatol Commun. 2019;3(8):1085\u201397. https:\/\/doi.org\/10.1002\/hep4.1368.","journal-title":"Hepatol Commun"},{"issue":"9","key":"603_CR267","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1111\/liv.14906","volume":"41","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Wang Y, Liu Y, Wang W, Tian X, Chen S, et al. A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis. Liver Int. 2021;41(9):2117\u201331. https:\/\/doi.org\/10.1111\/liv.14906.","journal-title":"Liver Int"},{"key":"603_CR268","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176334","volume":"966","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Wang W, Peng S, Lu Y, Du J, Cai W. Farnesoid X receptor agonist tropifexor detoxifies ammonia by regulating the glutamine metabolism and urea cycles in cholestatic livers. Eur J Pharmacol. 2024;966:176334. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176334.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"603_CR269","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100874","volume":"5","author":"CD Fuchs","year":"2023","unstructured":"Fuchs CD, Sroda N, Scharnagl H, Gupta R, Minto W, Stojakovic T, et al. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-\/- mouse model of sclerosing cholangitis. JHEP Rep. 2023;5(11):100874. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100874.","journal-title":"JHEP Rep"},{"issue":"6","key":"603_CR270","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","volume":"21","author":"M Trauner","year":"2023","unstructured":"Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, et al. Safety and sustained efficacy of the Farnesoid X Receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC. Clin Gastroenterol Hepatol. 2023;21(6):1552-1560.e2. https:\/\/doi.org\/10.1016\/j.cgh.2022.07.024.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"603_CR271","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R, Noureddin M, Kowdley KV, Kohli A, Sheikh A, Neff G, et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology. 2021;73(2):625\u201343. https:\/\/doi.org\/10.1002\/hep.31622.","journal-title":"Hepatology"},{"issue":"1","key":"603_CR272","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/biomedicines9010060","volume":"9","author":"P Schwabl","year":"2021","unstructured":"Schwabl P, Hambruch E, Budas GR, Supper P, Burnet M, Liles JT, et al. The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH mode Biomedicines. 2021;9(1):60. https:\/\/doi.org\/10.3390\/biomedicines9010060.","journal-title":"Biomedicines"},{"issue":"8","key":"603_CR273","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","volume":"63","author":"D Chianelli","year":"2020","unstructured":"Chianelli D, Rucker PV, Roland J. Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis. J Med Chem. 2020;63(8):3868\u201380. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01621.","journal-title":"J Med Chem"},{"key":"603_CR274","unstructured":"ClinicalTrials.gov: a randomized, patient and investigator blinded, placebo controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis (NASH). 2016. https:\/\/clinicaltrials.gov\/study\/NCT02913105. Accessed 16 Sep 2026."},{"issue":"3","key":"603_CR275","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","volume":"76","author":"V Ratziu","year":"2022","unstructured":"Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, et al. EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022;76(3):506\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2021.10.018.","journal-title":"J Hepatol"},{"issue":"7","key":"603_CR276","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1111\/liv.14490","volume":"40","author":"P An","year":"2020","unstructured":"An P, Wei G, Huang P, Li W, Qi X, Lin Y, et al. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020;40(7):1655\u201369. https:\/\/doi.org\/10.1111\/liv.14490.","journal-title":"Liver Int"},{"issue":"1","key":"603_CR277","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","volume":"75","author":"SA Harrison","year":"2021","unstructured":"Harrison SA, Bashir MR, Lee KJ, Shim-Lopez J, Lee J, Wagner B, et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol. 2021;75(1):25\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.047.","journal-title":"J Hepatol"},{"key":"603_CR278","doi-asserted-by":"publisher","first-page":"S682","DOI":"10.1016\/s0168-8278(20)31826-2","volume":"73","author":"S Veidal","year":"2020","unstructured":"Veidal S, Feigh M, T\u00f8lb\u00f8l K, Smith N, Wagner B. MET409, a potent, non-bile acid sustained FXR agonist, improves NAFLD activity score and exerts anti-fibrotic effects in a diet-induced obese mouse model of biopsy-confirmed fibrosing NASH. J Hepatol. 2020;73:S682\u20133. https:\/\/doi.org\/10.1016\/s0168-8278(20)31826-2.","journal-title":"J Hepatol"},{"issue":"13","key":"603_CR279","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1074\/jbc.m115.699504","volume":"291","author":"DP Kumar","year":"2016","unstructured":"Kumar DP, Asgharpour A, Mirshahi F, Park SH, Liu S, Imai Y, et al. Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet \u03b1 cells to promote glucose homeostasis. J Biol Chem. 2016;291(13):6626\u201340. https:\/\/doi.org\/10.1074\/jbc.m115.699504.","journal-title":"J Biol Chem"},{"issue":"4","key":"603_CR280","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/hep.24537","volume":"54","author":"A Baghdasaryan","year":"2011","unstructured":"Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, et al. Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO\u207b\u2083 output. Hepatology. 2011;54(4):1303\u201312. https:\/\/doi.org\/10.1002\/hep.24537.","journal-title":"Hepatology"},{"issue":"2","key":"603_CR281","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3748\/wjg.v24.i2.195","volume":"24","author":"JD Roth","year":"2018","unstructured":"Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, et al. INT-767 improves histopathological features in a diet-induced ob\/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol. 2018;24(2):195\u2013210. https:\/\/doi.org\/10.3748\/wjg.v24.i2.195.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"603_CR282","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102530","volume":"298","author":"XX Wang","year":"2022","unstructured":"Wang XX, Xie C, Libby AE, Ranjit S, Levi J, Myakala K, et al. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice. J Biol Chem. 2022;298(11):102530. https:\/\/doi.org\/10.1016\/j.jbc.2022.102530.","journal-title":"J Biol Chem"},{"issue":"3","key":"603_CR283","doi-asserted-by":"publisher","first-page":"G412","DOI":"10.1152\/ajpgi.00300.2018","volume":"316","author":"PD Finn","year":"2019","unstructured":"Finn PD, Rodriguez D, Kohler J, Jiang Z, Wan S, Blanco E, et al. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice. Am J Physiol Gastrointest Liver Physiol. 2019;316(3):G412\u201324. https:\/\/doi.org\/10.1152\/ajpgi.00300.2018.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"603_CR284","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1096\/fj.201801373rr","volume":"33","author":"A Carino","year":"2019","unstructured":"Carino A, Marchian\u00f2 S, Biagioli M, Bucci M, Vellecco V, Brancaleone V, et al. Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. FASEB J. 2019;33(2):2809\u201322. https:\/\/doi.org\/10.1096\/fj.201801373rr.","journal-title":"FASEB J"},{"issue":"11","key":"603_CR285","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141082","volume":"10","author":"B Renga","year":"2015","unstructured":"Renga B, Cipriani S, Carino A, Simonetti M, Zampella A, Fiorucci S. Reversal of endothelial dysfunction by GPBAR1 agonism in portal hypertension involves a AKT\/FOXOA1 dependent regulation of H2S generation and endothelin-1. PLoS ONE. 2015;10(11):e0141082. https:\/\/doi.org\/10.1371\/journal.pone.0141082.","journal-title":"PLoS ONE"},{"issue":"2","key":"603_CR286","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16235","volume":"45","author":"C Di Giorgio","year":"2025","unstructured":"Di Giorgio C, Urbani G, Marchian\u00f2 S, Biagioli M, Bordoni M, Bellini R, et al. Liver GPBAR1 associates with immune dysfunction in primary sclerosing cholangitis and its activation attenuates cholestasis in Abcb4-\/- mice. Liver Int. 2025;45(2):e16235. https:\/\/doi.org\/10.1111\/liv.16235.","journal-title":"Liver Int"},{"issue":"10","key":"603_CR287","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/hep4.1108","volume":"1","author":"M Zhou","year":"2017","unstructured":"Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. Hepatol Commun. 2017;1(10):1024\u201342. https:\/\/doi.org\/10.1002\/hep4.1108.","journal-title":"Hepatol Commun"},{"issue":"7","key":"603_CR288","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/s2468-1253(22)00017-6","volume":"7","author":"SA Harrison","year":"2022","unstructured":"Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2022;7(7):603\u201316. https:\/\/doi.org\/10.1016\/s2468-1253(22)00017-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10126","key":"603_CR289","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/s0140-6736(18)30474-4","volume":"391","author":"SA Harrison","year":"2018","unstructured":"Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;391(10126):1174\u201385. https:\/\/doi.org\/10.1016\/s0140-6736(18)30474-4.","journal-title":"Lancet"},{"issue":"3","key":"603_CR290","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hep.28257","volume":"63","author":"M Zhou","year":"2016","unstructured":"Zhou M, Learned RM, Rossi SJ, DePaoli AM, Tian H, Ling L. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology. 2016;63(3):914\u201329. https:\/\/doi.org\/10.1002\/hep.28257.","journal-title":"Hepatology"},{"issue":"3","key":"603_CR291","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","volume":"70","author":"GM Hirschfield","year":"2019","unstructured":"Hirschfield GM, Chazouill\u00e8res O, Drenth JP, Thorburn D, Harrison SA, Landis CS, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol. 2019;70(3):483\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.035.","journal-title":"J Hepatol"},{"key":"603_CR292","unstructured":"ClinicalTrials.gov: a phase 2b\/3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Aldafermin in subjects with primary sclerosing cholangitis (ALPINE-PSC). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06654726. Accessed 16 Sep 2026."},{"issue":"2","key":"603_CR293","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Lopez P, Lawitz EJ, Lucas KJ, Loeffler J, Kim W, et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial. Nat Med. 2023;29(2):392\u2013400. https:\/\/doi.org\/10.1038\/s41591-022-02200-8.","journal-title":"Nat Med"},{"issue":"357","key":"603_CR294","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf4823","volume":"8","author":"A Rao","year":"2016","unstructured":"Rao A, Kosters A, Mells JE, Zhang W, Setchell KDR, Amanso AM, et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med. 2016;8(357):357ra122. https:\/\/doi.org\/10.1126\/scitranslmed.aaf4823.","journal-title":"Sci Transl Med"},{"issue":"9","key":"603_CR295","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/s2468-1253(22)00093-0","volume":"7","author":"RJ Thompson","year":"2022","unstructured":"Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(9):830\u201342. https:\/\/doi.org\/10.1016\/s2468-1253(22)00093-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10311","key":"603_CR296","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/s0140-6736(21)01256-3","volume":"398","author":"E Gonzales","year":"2021","unstructured":"Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021;398(10311):1581\u201392. https:\/\/doi.org\/10.1016\/s0140-6736(21)01256-3.","journal-title":"Lancet"},{"issue":"7","key":"603_CR297","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/s2468-1253(24)00080-3","volume":"9","author":"AG Miethke","year":"2024","unstructured":"Miethke AG, Moukarzel A, Porta G, Covarrubias Esquer J, Czubkowski P, Ordonez F, et al. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(7):620\u201331. https:\/\/doi.org\/10.1016\/s2468-1253(24)00080-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"603_CR298","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/s2468-1253(25)00192-x","volume":"11","author":"GM Hirschfield","year":"2026","unstructured":"Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22\u201333. https:\/\/doi.org\/10.1016\/s2468-1253(25)00192-x.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"603_CR299","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/s2468-1253(18)30123-7","volume":"3","author":"A Nakajima","year":"2018","unstructured":"Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(8):537\u201347. https:\/\/doi.org\/10.1016\/s2468-1253(18)30123-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"603_CR300","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cpt.744","volume":"103","author":"A Blank","year":"2018","unstructured":"Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, et al. The NTCP-inhibitor myrcludex B: effects on bile acid disposition and tenofovir pharmacokinetics. Clin Pharmacol Ther. 2018;103(2):341\u20138. https:\/\/doi.org\/10.1002\/cpt.744.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"603_CR301","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/hep.29888","volume":"68","author":"D Slijepcevic","year":"2018","unstructured":"Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, et al. Na+ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. Hepatology. 2018;68(3):1057\u201369. https:\/\/doi.org\/10.1002\/hep.29888.","journal-title":"Hepatology"},{"issue":"3","key":"603_CR302","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcmgh.2020.04.009","volume":"10","author":"JM Donkers","year":"2020","unstructured":"Donkers JM, Roscam Abbing RLP, van Weeghel M, Levels JHM, Boelen A, Schinkel AH, et al. Inhibition of hepatic bile acid uptake by myrcludex B promotes glucagon-like peptide-1 release and reduces obesity. Cell Mol Gastroenterol Hepatol. 2020;10(3):451\u201366. https:\/\/doi.org\/10.1016\/j.jcmgh.2020.04.009.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"8","key":"603_CR303","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100594","volume":"65","author":"B Porteiro","year":"2024","unstructured":"Porteiro B, Roscam Abbing RLP, In het Panhuis W, de Waart DR, Duijst S, Bolt I, et al. Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1-\/-Ldlr-\/- mice. J Lipid Res. 2024;65(8):100594. https:\/\/doi.org\/10.1016\/j.jlr.2024.100594.","journal-title":"J Lipid Res"},{"issue":"6","key":"603_CR304","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jhep.2024.12.044","volume":"82","author":"E Degasperi","year":"2025","unstructured":"Degasperi E, Anolli MP, Jachs M, Reiberger T, De Ledinghen V, Metivier S, et al. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. J Hepatol. 2025;82(6):1012\u201322. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.044.","journal-title":"J Hepatol"},{"issue":"1","key":"603_CR305","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/nejmoa2213429","volume":"389","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389(1):22\u201332. https:\/\/doi.org\/10.1056\/nejmoa2213429.","journal-title":"N Engl J Med"},{"issue":"1","key":"603_CR306","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cmet.2011.11.010","volume":"15","author":"RA Haeusler","year":"2012","unstructured":"Haeusler RA, Pratt-Hyatt M, Welch CL, Klaassen CD, Accili D. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 2012;15(1):65\u201374. https:\/\/doi.org\/10.1016\/j.cmet.2011.11.010.","journal-title":"Cell Metab"},{"issue":"21","key":"603_CR307","doi-asserted-by":"publisher","DOI":"10.1172\/jci152961","volume":"132","author":"S Zhong","year":"2022","unstructured":"Zhong S, Ch\u00e8vre R, Casta\u00f1o Mayan D, Corlian\u00f2 M, Cochran BJ, Sem KP, et al. Haploinsufficiency of CYP8B1 associates with increased insulin sensitivity in humans. J Clin Invest. 2022;132(21):e152961. https:\/\/doi.org\/10.1172\/jci152961.","journal-title":"J Clin Invest"},{"issue":"4","key":"603_CR308","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.2337\/db14-0716","volume":"64","author":"A Kaur","year":"2015","unstructured":"Kaur A, Patankar JV, de Haan W, Ruddle P, Wijesekara N, Groen AK, et al. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes. 2015;64(4):1168\u201379. https:\/\/doi.org\/10.2337\/db14-0716.","journal-title":"Diabetes"},{"issue":"7","key":"603_CR309","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1096\/fj.201701084rr","volume":"32","author":"R Chevre","year":"2018","unstructured":"Chevre R, Trigueros-Motos L, Casta\u00f1o D, Chua T, Corlian\u00f2 M, Patankar JV, et al. Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice. FASEB J. 2018;32(7):3792\u2013802. https:\/\/doi.org\/10.1096\/fj.201701084rr.","journal-title":"FASEB J"},{"issue":"13","key":"603_CR310","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/circulationaha.120.045373","volume":"145","author":"I Semova","year":"2022","unstructured":"Semova I, Levenson AE, Krawczyk J, Bullock K, Gearing ME, Ling AV, et al. Insulin prevents hypercholesterolemia by suppressing 12\u03b1-hydroxylated bile acids. Circulation. 2022;145(13):969\u201382. https:\/\/doi.org\/10.1161\/circulationaha.120.045373.","journal-title":"Circulation"},{"issue":"1","key":"603_CR311","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"GM Hirschfield","year":"2017","unstructured":"Hirschfield GM, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M, et al. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u201372. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022.","journal-title":"J Hepatol"},{"issue":"3","key":"603_CR312","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1053\/jhep.2002.36088","volume":"36","author":"G Paumgartner","year":"2002","unstructured":"Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36(3):525\u201331. https:\/\/doi.org\/10.1053\/jhep.2002.36088.","journal-title":"Hepatology"},{"key":"603_CR313","doi-asserted-by":"publisher","unstructured":"Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 1994;330(19):1342\u20137. \nhttps:\/\/doi.org\/10.1056\/NEJM199405123301903.","DOI":"10.1056\/NEJM199405123301903"},{"issue":"12","key":"603_CR314","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/s2468-1253(21)00301-0","volume":"6","author":"S Haal","year":"2021","unstructured":"Haal S, Guman MSS, Boerlage TCC, Acherman YIZ, de Brauw LM, Bruin S, et al. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial. Lancet Gastroenterol Hepatol. 2021;6(12):993\u20131001. https:\/\/doi.org\/10.1016\/s2468-1253(21)00301-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"603_CR315","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1136\/gutjnl-2024-333297","volume":"74","author":"C Zhu","year":"2025","unstructured":"Zhu C, Boucheron N, Al-Rubaye O, Chung BK, Thorbj\u00f8rnsen LW, K\u00f6cher T, et al. 24-Nor-ursodeoxycholic acid improves intestinal inflammation by targeting TH17 pathogenicity and transdifferentiation. Gut. 2025;74(7):1079\u201393. https:\/\/doi.org\/10.1136\/gutjnl-2024-333297.","journal-title":"Gut"},{"issue":"5","key":"603_CR316","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2021.06.036","volume":"75","author":"C Zhu","year":"2021","unstructured":"Zhu C, Boucheron N, M\u00fcller AC, M\u00e1jek P, Claudel T, Halilbasic E, et al. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation. J Hepatol. 2021;75(5):1164\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.036.","journal-title":"J Hepatol"},{"issue":"3","key":"603_CR317","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","volume":"67","author":"P Fickert","year":"2017","unstructured":"Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, F\u00e4rkkil\u00e4 M, et al. Norursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549\u201358. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.009.","journal-title":"J Hepatol"},{"issue":"2","key":"603_CR318","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659\u2013702. https:\/\/doi.org\/10.1002\/hep.32771.","journal-title":"Hepatology"},{"issue":"4","key":"603_CR319","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1053\/j.gastro.2009.07.043","volume":"137","author":"E Gonzales","year":"2009","unstructured":"Gonzales E, Gerhardt MF, Fabre M, Setchell KDR, Davit\u2013Spraul A, Vincent I, et al. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy. Gastroenterology. 2009;137(4):1310-1320.e1-3. https:\/\/doi.org\/10.1053\/j.gastro.2009.07.043.","journal-title":"Gastroenterology"},{"issue":"4","key":"603_CR320","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/mpg.0000000000002618","volume":"70","author":"JE Heubi","year":"2020","unstructured":"Heubi JE, Setchell KDR. Open-label phase 3 continuation study of cholic acid in patients with inborn errors of bile acid synthesis. J Pediatr Gastroenterol Nutr. 2020;70(4):423\u20139. https:\/\/doi.org\/10.1097\/mpg.0000000000002618.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"603_CR321","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000490095","volume":"12","author":"JE Heubi","year":"2018","unstructured":"Heubi JE, Setchell KDR, Bove KE. Long-term cholic acid therapy in zellweger spectrum disorders. Case Rep Gastroenterol. 2018;12(2):360\u201372. https:\/\/doi.org\/10.1159\/000490095.","journal-title":"Case Rep Gastroenterol"},{"issue":"6","key":"603_CR322","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s10545-016-9962-9","volume":"39","author":"K Berendse","year":"2016","unstructured":"Berendse K, Klouwer FCC, Koot BGP, Kemper EM, Ferdinandusse S, Koelfat KVK, et al. Cholic acid therapy in Zellweger spectrum disorders. J Inherit Metab Dis. 2016;39(6):859\u201368. https:\/\/doi.org\/10.1007\/s10545-016-9962-9.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"603_CR323","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.70069","volume":"48","author":"T Zubarioglu","year":"2025","unstructured":"Zubarioglu T, Kad\u0131o\u011flu\u2010Y\u0131lmaz B, K\u00f6se E, Teke\u2010K\u0131sa P, Balc\u0131 MC, Yaz\u0131c\u0131 H, et al. Long-term outcomes of chenodeoxycholic acid therapy for cerebrotendinous xanthomatosis: a nationwide study on prognostic factors and treatment response. J Inherit Metab Dis. 2025;48(4):e70069. https:\/\/doi.org\/10.1002\/jimd.70069.","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"603_CR324","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2025.101449","volume":"27","author":"YY Kisanuki","year":"2025","unstructured":"Kisanuki YY, Nobrega PR, Himes R, Jayadev S, Bernat JA, Prakash V, et al. Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): a randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 study. Genet Med. 2025;27(7):101449. https:\/\/doi.org\/10.1016\/j.gim.2025.101449.","journal-title":"Genet Med"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00603-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:03:04Z","timestamp":1790974984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00603-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":324,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00603-4","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"193"}}